CA2613732A1 - Thermoreversible immuno-adjuvant emulsion - Google Patents
Thermoreversible immuno-adjuvant emulsion Download PDFInfo
- Publication number
- CA2613732A1 CA2613732A1 CA002613732A CA2613732A CA2613732A1 CA 2613732 A1 CA2613732 A1 CA 2613732A1 CA 002613732 A CA002613732 A CA 002613732A CA 2613732 A CA2613732 A CA 2613732A CA 2613732 A1 CA2613732 A1 CA 2613732A1
- Authority
- CA
- Canada
- Prior art keywords
- emulsion
- oil
- water
- phase
- squalene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000839 emulsion Substances 0.000 title claims abstract description 199
- 230000001571 immunoadjuvant effect Effects 0.000 title description 3
- 239000000568 immunological adjuvant Substances 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 122
- 239000000427 antigen Substances 0.000 claims abstract description 63
- 102000036639 antigens Human genes 0.000 claims abstract description 63
- 108091007433 antigens Proteins 0.000 claims abstract description 63
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims abstract description 48
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims abstract description 48
- 229940031439 squalene Drugs 0.000 claims abstract description 48
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims abstract description 48
- 229960005486 vaccine Drugs 0.000 claims abstract description 46
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 35
- -1 polyoxyethylene Polymers 0.000 claims abstract description 29
- 239000002671 adjuvant Substances 0.000 claims abstract description 26
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 23
- 230000002163 immunogen Effects 0.000 claims abstract description 23
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 23
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 22
- 239000007764 o/w emulsion Substances 0.000 claims abstract description 22
- 150000005215 alkyl ethers Chemical class 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003125 aqueous solvent Substances 0.000 claims abstract description 11
- 239000012071 phase Substances 0.000 claims description 41
- 230000008569 process Effects 0.000 claims description 32
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 28
- 229930195725 Mannitol Natural products 0.000 claims description 28
- 239000000594 mannitol Substances 0.000 claims description 28
- 235000010355 mannitol Nutrition 0.000 claims description 28
- 239000004094 surface-active agent Substances 0.000 claims description 27
- 239000008346 aqueous phase Substances 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- 150000005846 sugar alcohols Chemical class 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 238000004108 freeze drying Methods 0.000 claims description 7
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical group FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 239000001593 sorbitan monooleate Substances 0.000 claims description 5
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 5
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 239000002577 cryoprotective agent Substances 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 239000004386 Erythritol Substances 0.000 claims description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 3
- 235000019414 erythritol Nutrition 0.000 claims description 3
- 229940009714 erythritol Drugs 0.000 claims description 3
- 229960005150 glycerol Drugs 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 229960001855 mannitol Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 229960002920 sorbitol Drugs 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims 1
- 238000009826 distribution Methods 0.000 abstract description 4
- 238000000614 phase inversion technique Methods 0.000 abstract 1
- 239000000872 buffer Substances 0.000 description 54
- 230000003612 virological effect Effects 0.000 description 44
- 241000699670 Mus sp. Species 0.000 description 29
- 238000002965 ELISA Methods 0.000 description 28
- 206010022000 influenza Diseases 0.000 description 25
- 230000003053 immunization Effects 0.000 description 24
- 229940031418 trivalent vaccine Drugs 0.000 description 23
- 238000002649 immunization Methods 0.000 description 22
- 239000003921 oil Substances 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 18
- 230000004044 response Effects 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 241000700605 Viruses Species 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000011725 BALB/c mouse Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000005259 measurement Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000003068 static effect Effects 0.000 description 6
- 239000007762 w/o emulsion Substances 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 101000739160 Homo sapiens Secretoglobin family 3A member 1 Proteins 0.000 description 4
- 241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 description 4
- 101710149951 Protein Tat Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102100037268 Secretoglobin family 3A member 1 Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000000240 adjuvant effect Effects 0.000 description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 4
- 229960001231 choline Drugs 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000008348 humoral response Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 3
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000008366 buffered solution Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000185 hemagglutinin Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000000899 immune system response Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 2
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 101150029683 gB gene Proteins 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 238000011795 OF1 mouse Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- LUXUAZKGQZPOBZ-SAXJAHGMSA-N [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O LUXUAZKGQZPOBZ-SAXJAHGMSA-N 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940073669 ceteareth 20 Drugs 0.000 description 1
- 229940056318 ceteth-20 Drugs 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000002477 conductometry Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 125000006159 dianhydride group Chemical group 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000013230 female C57BL/6J mice Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000037801 influenza A (H1N1) Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940095127 oleth-20 Drugs 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000010587 phase diagram Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940100459 steareth-20 Drugs 0.000 description 1
- 229940100458 steareth-21 Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Nanotechnology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Colloid Chemistry (AREA)
Abstract
The invention relates to an oil-in-water adjuvant emulsion including at least squalene, an aqueous solvent, a nonionic surfactant which is polyoxyethylene alkyl ether and a thermoreversible hydrophobic nonionic surfactant, in which adjuvant the size of 90 % of the oil droplet volume distribution is less than 200 nm. The invention also relates to a method of preparing an immunogenic composition, wherein at least one vaccine antigen is mixed with an oil-in-water emulsion. The invention is characterised in that the oil-in-water emulsion is obtained via a temperature-variation phase inversion method.
Description
THERMOREVERSIBLE IMMUNO-ADJUVANT EMULSION
The present invention relates to the field of vaccines; more particularly, the invention relates to the field of vaccines comprising an adjuvant emulsion.
Many vaccines which contain one or more adjuvants exist in the prior art. US
patent 6 299 884 discloses in particular an adjuvant formulation comprising an oil-in-water emulsion, in which the size of the oil droplets is between 100 and 1000 nm.
This emulsion is obtained by means of a high pressure homogenizer (microfluidizer), in the course of a manufacturing process using high mechanical energies in order to obtain shear forces that are sufficiently great to reduce the size of the oil drops.
According to this teaching, while the minimum value of the size range of the drops obtained is 100 nm, the mean value is much higher and is, at best, in the region of 170 nm, more generally in the region of 500 nm.
It is desirable to have available a formulation that is an alternative to that proposed in that patent, that can be obtained by means of a simpler process (not requiring any specific shear technology) that is a low-energy process while at the same time being reproducible and completely reliable; in addition, the adjuvant formulation must make it possible to effectively adjuvant vaccines, by making it possible in particular to increase the immune response obtained or to decrease the dose of antigen present, while at the same time exhibiting no sign of toxicity that would be detrimental to its completely safe administration.
To achieve this aim, a subject of the present invention is an oil-in-water adjuvant emulsion characterized in that it comprises at least:
- squalene, - an aqueous solvent, - a hydrophilic nonionic surfactant which is a polyoxyethylene alkyl ether, - a hydrophobic nonionic surfactant, in that it is thermoreversible and in that 90% of the population by volume of the oil drop has a size less than 200 nm.
According to the invention, such an emulsion may be obtained by means of a phase inversion temperature process, which provides a very large advantage from an industrial point of view. Such a process provides all the guarantees of safety and of profitability necessary for the pliarmaceutical industry. In addition, by virtue of this process, it is possible to obtain a monodisperse emulsion, the droplet size of which is very small, which renders the emulsion thus obtained particularly stable and readily filterable by means of sterilizing filters, the cutoff threshold of which is 200 nm.
According to a particular characteristic, 90% of the population by volume (or d90) of the oil drops has a size less than 160 nm, and even less than 150 nm.
According to a particular embodiment of the invention, the emulsion according to the invention also comprises an alditol; this makes it possible to obtain a phase inversion at a temperature below that which would be necessary for the same composition not containing any alditol, which makes it possible to reduce the production costs and also the risks of thermal denaturation of the constituents of the emulsion.
According to a particularly advantageous embodiment, the hydrophobic nonionic surfactant of the invention is a sorbitan ester or a mannide ester. Such surfactants have the advantage of being able to be used entirely safely in injectable solutions.
According to a particular embodiment of the invention, the emulsion also comprises an alkylpolyglycoside and a cryoprotective agent such as a sugar, in particular dodecylmaltoside and/or sucrose.
Thus, it is possible to obtain a lyophilizable emulsion which, after lyophilization and reconstitution, recovers its properties, in particular particle size properties, i.e. the lyophilized and then reconstituted emulsion is still monodisperse and consists of oil droplets, 90% of the population by volume of which has a size of less than 200 nm.
This is particularly important for the field of vaccines which must sometimes, for reasons of stability (either of certain antigens, or of certain adjuvants), be conserved in lyophilized form.
A subject of the invention is also a process for preparing an immunogenic composition according to which at least one vaccine antigen is mixed with an oil-in-water emulsion, characterized in that the oil-in-water emulsion is obtained by means of a phase inversion temperature process.
According to one embodiment, the process according to the invention comprises at least one step of preparing the oil-in-water emulsion by cooling a water-in-oil inverse emulsion, which comprises at least:
- squalene, - an aqueous solvent, - a hydrophilic nonionic surfactant which is a polyoxyethylene alkyl ether, - a hydrophobic nonionic surfactant.
By virtue of such a process, which is very advantageous from an industrial point of view, a stable immunogenic composition is obtained which is very effective even at a very low dose of antigens.
In addition, by virtue of the preparation process used, the droplets of oil of the emulsion are all calibrated over the same very small size; in fact, when the particle size properties (size and size distribution) are measured, it is noted that the emulsion is a monodisperse emulsion, with a Gaussian-type distribution curve, which is very narrow and centered around a low value, generally around 80-90 nm.
According to a specific embodiment of the process according to the invention, the water-in-oil inverse emulsion is obtained by mixing squalene, an aqueous solvent, a hydrophilic nonionic surfactant which is polyoxyethylene alkyl ether, and a hydrophobic nonionic surfactant so as to obtain, first of all, an oil-in-water coarse emulsion, and this emulsion is then heated to at least the phase-inversion temperature so as to obtain the inverse emulsion. Carrying out the process in such a way has the advantage of limiting the time during which the various constituents of the emulsion are subjected to a high temperature.
According to another embodiment, the process according to the invention comprises the following steps:
- firstly, the aqueous phase comprising the aqueous solvent and the polyoxy-ethylene alkyl ether and, secondly, the oily phase comprising the squalene and the hydrophobic surfactant are heated, separately, to a temperature at least equal to the phase-inversion temperature, and then - the 2 phases are mixed so as to obtain a water-in-oil inverse emulsion.
According to a specific embodiment of the invention, each of the aqueous and oily phases is heated separately, before mixing, to a temperature below the phase-inversion temperature. The 2 phases are then mixed so as to obtain a water-in-oil emulsion; the whole is then heated to a temperature at least equal to the phase-inversion temperature so as to obtain the water-in-oil inverse emulsion.
The present invention relates to the field of vaccines; more particularly, the invention relates to the field of vaccines comprising an adjuvant emulsion.
Many vaccines which contain one or more adjuvants exist in the prior art. US
patent 6 299 884 discloses in particular an adjuvant formulation comprising an oil-in-water emulsion, in which the size of the oil droplets is between 100 and 1000 nm.
This emulsion is obtained by means of a high pressure homogenizer (microfluidizer), in the course of a manufacturing process using high mechanical energies in order to obtain shear forces that are sufficiently great to reduce the size of the oil drops.
According to this teaching, while the minimum value of the size range of the drops obtained is 100 nm, the mean value is much higher and is, at best, in the region of 170 nm, more generally in the region of 500 nm.
It is desirable to have available a formulation that is an alternative to that proposed in that patent, that can be obtained by means of a simpler process (not requiring any specific shear technology) that is a low-energy process while at the same time being reproducible and completely reliable; in addition, the adjuvant formulation must make it possible to effectively adjuvant vaccines, by making it possible in particular to increase the immune response obtained or to decrease the dose of antigen present, while at the same time exhibiting no sign of toxicity that would be detrimental to its completely safe administration.
To achieve this aim, a subject of the present invention is an oil-in-water adjuvant emulsion characterized in that it comprises at least:
- squalene, - an aqueous solvent, - a hydrophilic nonionic surfactant which is a polyoxyethylene alkyl ether, - a hydrophobic nonionic surfactant, in that it is thermoreversible and in that 90% of the population by volume of the oil drop has a size less than 200 nm.
According to the invention, such an emulsion may be obtained by means of a phase inversion temperature process, which provides a very large advantage from an industrial point of view. Such a process provides all the guarantees of safety and of profitability necessary for the pliarmaceutical industry. In addition, by virtue of this process, it is possible to obtain a monodisperse emulsion, the droplet size of which is very small, which renders the emulsion thus obtained particularly stable and readily filterable by means of sterilizing filters, the cutoff threshold of which is 200 nm.
According to a particular characteristic, 90% of the population by volume (or d90) of the oil drops has a size less than 160 nm, and even less than 150 nm.
According to a particular embodiment of the invention, the emulsion according to the invention also comprises an alditol; this makes it possible to obtain a phase inversion at a temperature below that which would be necessary for the same composition not containing any alditol, which makes it possible to reduce the production costs and also the risks of thermal denaturation of the constituents of the emulsion.
According to a particularly advantageous embodiment, the hydrophobic nonionic surfactant of the invention is a sorbitan ester or a mannide ester. Such surfactants have the advantage of being able to be used entirely safely in injectable solutions.
According to a particular embodiment of the invention, the emulsion also comprises an alkylpolyglycoside and a cryoprotective agent such as a sugar, in particular dodecylmaltoside and/or sucrose.
Thus, it is possible to obtain a lyophilizable emulsion which, after lyophilization and reconstitution, recovers its properties, in particular particle size properties, i.e. the lyophilized and then reconstituted emulsion is still monodisperse and consists of oil droplets, 90% of the population by volume of which has a size of less than 200 nm.
This is particularly important for the field of vaccines which must sometimes, for reasons of stability (either of certain antigens, or of certain adjuvants), be conserved in lyophilized form.
A subject of the invention is also a process for preparing an immunogenic composition according to which at least one vaccine antigen is mixed with an oil-in-water emulsion, characterized in that the oil-in-water emulsion is obtained by means of a phase inversion temperature process.
According to one embodiment, the process according to the invention comprises at least one step of preparing the oil-in-water emulsion by cooling a water-in-oil inverse emulsion, which comprises at least:
- squalene, - an aqueous solvent, - a hydrophilic nonionic surfactant which is a polyoxyethylene alkyl ether, - a hydrophobic nonionic surfactant.
By virtue of such a process, which is very advantageous from an industrial point of view, a stable immunogenic composition is obtained which is very effective even at a very low dose of antigens.
In addition, by virtue of the preparation process used, the droplets of oil of the emulsion are all calibrated over the same very small size; in fact, when the particle size properties (size and size distribution) are measured, it is noted that the emulsion is a monodisperse emulsion, with a Gaussian-type distribution curve, which is very narrow and centered around a low value, generally around 80-90 nm.
According to a specific embodiment of the process according to the invention, the water-in-oil inverse emulsion is obtained by mixing squalene, an aqueous solvent, a hydrophilic nonionic surfactant which is polyoxyethylene alkyl ether, and a hydrophobic nonionic surfactant so as to obtain, first of all, an oil-in-water coarse emulsion, and this emulsion is then heated to at least the phase-inversion temperature so as to obtain the inverse emulsion. Carrying out the process in such a way has the advantage of limiting the time during which the various constituents of the emulsion are subjected to a high temperature.
According to another embodiment, the process according to the invention comprises the following steps:
- firstly, the aqueous phase comprising the aqueous solvent and the polyoxy-ethylene alkyl ether and, secondly, the oily phase comprising the squalene and the hydrophobic surfactant are heated, separately, to a temperature at least equal to the phase-inversion temperature, and then - the 2 phases are mixed so as to obtain a water-in-oil inverse emulsion.
According to a specific embodiment of the invention, each of the aqueous and oily phases is heated separately, before mixing, to a temperature below the phase-inversion temperature. The 2 phases are then mixed so as to obtain a water-in-oil emulsion; the whole is then heated to a temperature at least equal to the phase-inversion temperature so as to obtain the water-in-oil inverse emulsion.
According to a particular embodiment, the preparation process according to the invention also comprises a lyophilization step. Thus, the process according to the invention can be used for the preparation of immunogenic compositions comprising antigens which must be conserved in lyophilized form for reasons of stability.
Many other advantages of the present invention will become apparent in the course of the following description.
For the purposes of description of the invention, the parameters d50 and d90 mentioned in the present patent application are values relating to volume; the d50 value signifies the value of 50% of the drop population by volume.
For the purpose of the invention, the tenn "oil-in-water emulsion" is intended to mean a dispersion of an oily phase in an aqueous phase which may consist either of water or of a saline solution, that is optionally buffered. According to a particular embodiment of the invention, the aqueous phase of the emulsion consists of a buffer, such as Dulbecco's phosphate buffered solutions (D-PBS, without calcium or magnesium).
The term "adjuvant emulsion" is intended to mean an immunoadjuvant emulsion, i.e.
an emulsion capable of modifying the response of the immune system induced during the administration of an antigen, compared with the response obtained in the absence of the emulsion; this inunune system response may be reflected by antibody production or by activation of certain cells, in particular antigen-presenting cells (for example, dendritic cells), T lymphocytes and B lymphocytes. This cellular activation can be demonstrated by the presence of activation markers at the surface of the cells or by the release of cytokines. The modification of the immune response induced by the adjuvant emulsion may be quantitative in nature, i.e. an increase in the induced response is obtained, or qualitative in nature, i.e. a response that is different in nature or has a different orientation is obtained, or else an additional response is obtained.
The term "adjuvant emulsion" is also intended to mean an emulsion that makes it possible to reduce the amount of antigens administered for the same induced response.
For the purpose of the present invention, the term "immunogenic composition"
is intended to mean a composition comprising at least one antigen and that can be administered to humans or to animals in order to induce an immune system response.
This response may be a humoral response (antibody production) or a cellular response (proliferation and/or activation of immune cells). The immunogenic composition may be a composition for prophylactic purposes or for therapeutic purposes, or else both.
The immunogenic composition obtained according to the invention can be administered via any of the routes normally used or recommended for vaccines:
parenterally or mucosally, and can be in various forms, in particular a liquid or lyophilized form. It can be administered by means of a syringe or by means of a needle-free injector for intramuscular, subcutaneous or intradermal injection, or by means of a nasal spray.
For the purpose of the present invention, the term "antigen" is intended to mean any antigen that can be used in a vaccine, whether it involves a whole microorganism or a subunit antigen, regardless of its nature; the antigen may in fact be a peptide, a protein, a glycoprotein, a polysaccharide, a glycolipid, a lipopeptide, etc.
The adjuvant emulsion according to the invention is particularly suitable for viral antigens; particularly good results have in fact been obtained with antigens of the human cytomegalovirus, of the human immunodeficiency virus, and of the flu virus.
As regards the flu virus antigens, it is possible to use antigens that come from a single viral strain, or from a mixture of various strains. It is possible to use antigens derived from viruses cultured conventionally on eggs, or on cells. By means of the invention, it has been noted that whether for a single strain or for a mixture of strains, it is possible to obtain a satisfactory response of the immune system while at the same time very substantially reducing the amount of antigens present in the vaccine dose.
This may be of particularly great value in the case of the preparation of a vaccine against a flu pandemic, where it must be possible to produce, in a very short period of time, very large amounts of vaccine doses.
According to the invention, the oil-in-water emulsion comprises squalene, which is an oil initially originating from shark liver; it is an oil whose empirical chemical formula is C30H50, comprising 6 double bonds; this oil is metabolizable and has qualities that allow it to be used in an injectable pharmaceutical product. Squalene of plant origin, extracted from olive oil, also exists. Good results have in particular been obtained using the squalene provided by the company Fluka, which is of animal origin.
The amounts of squalene used for the preparation of a concentrated emulsion are advantageously between 5 and 45%; this concentrated emulsion is subsequently diluted during the preparation of immunogenic compositions so as to prepare immunizing doses in which the amount of squalene is between 0.5 and 5%. This dilution can be carried out by simply mixing the adjuvant emulsion according to the invention and the suspension comprising the antigen.
According to the invention, the emulsion comprises a nonionic hydrophilic surfactant, the value of the hydrophilic/lipophilic balance or HLB of which is greater than or equal to 10 and which belongs to the chemical group of polyoxyethylene alkyl ethers (PAEs), also known as polyoxyethylenated fatty alcohol ethers, or n-alkyl polyoxyethylene glycol ethers. These nonionic surfactants are obtained by chemical condensation between a fatty alcohol and ethylene oxide. They have a general chemical formula of the type CH3(CH2)X-(O-CHZ-CH2)õOH in which n denotes the number of ethylene oxide units and is usually between 10 and 60, and x + 1 is the carbon number, depending on the fatty alcohols used. In general, these products are mixtures of polymers with hydrocarbon-based chains of similar length.
The emulsion according to the invention usually comprises a single hydrophilic PAE.
A mixture of several PAEs is also suitable insofar as the overall HLB value is _ 10.
The polyoxyethylenated fatty alcohol ethers suitable for the subject of the invention can be in a liquid or solid form at ambient temperature. Among the solid compounds, preference is given to those which dissolve directly in the aqueous phase or which do not require substantial heating.
Insofar as the number of ethylene oxide units is sufficient, the polyoxyethylenated ethers of lauryl, myristyl, cetyl, oleyl and/or stearyl alcohols are particularly suitable for the subject of the invention. They can in particular be found in the range of products known under the trade names Brij for the products sold by the company ICI America's Inc., Eumulgin for the products sold by the company Cognis, or Simulsol for the products sold by the company SEPPIC.
A particularly preferred emulsion according to the invention contains, as nonionic hydrophilic surfactant, a polyoxyethylene alkyl ether chosen from the group consisting of ceteareth-12 (sold under the name Eumulgin B1), ceteareth-20 (Eumulgin(R B2), steareth-21 (Eumulgin0 S21), ceteth-20 (Simulsol(D 58 or BrijO 58), ceteth-10 (BrijO 56), steareth-10 (Brij(V 76), steareth-20 (Brij(D
78), oleth-10 (BrijO 96 or Brij(D 97) and oleth-20 (BrijO 98 or BrijO 99). The number assigned to each chemical name corresponds to the number of ethylene oxide units in the chemical formula.
Good results have been obtained with the product BrijO 56. A compound that is particularly suitable and preferred due to its semisynthetic origin is the polyoxy-ethylene (12) cetostearyl ether supplied by the company Cognis under the name EumulginT"'B1. This compound is a mixture of CH3(CH2)15-(O-CH2-CH2)12-OH and of CH3(CH2)17-(O-CH2-CH2)12-OH.
According to the invention, the adjuvant emulsion also comprises a hydrophobic nonionic surfactant; it must be a surfactant that can be used in the pharmaceutical industry; among surfactants that are suitable in this regard, mention may be made of sorbitan esters and mannide esters; the sorbitan esters are obtained by reaction of a fatty acid and of a mixture of partial esters of sorbitol and its mono- and dianhydrides;
this may involve a mono-, a di- or a triester, or even a mixture; they are hydrophobic surfactants for which the overall hydrophilic-lipophilic balance (HLB), is less than 9, and preferably less than 6. They can be found in particular in the range of surfactants sold by the company ICI Americas Inc. under the name Span , or by the company Cognis under the name DehymulsTM, or by the company ICI under the name ArlacelTM; as examples of surfactants that are particularly suitable, mention may be made of the sorbitan monooleate sold under the name Dehymuls SMOTM or Span 80.
Among the surfactants consisting of mannide esters, mention may be made of the mannide monooleate sold by the company Sigma, or by the company Seppic under the name Montanide 80TM
By virtue of the selection of these specific surfactants among all the surfactants proposed in the prior art for preparing emulsions, it has now been found that it is possible, very advantageously, to produce an oil-in-water adjuvant emulsion using a phase-inversion process.
Many other advantages of the present invention will become apparent in the course of the following description.
For the purposes of description of the invention, the parameters d50 and d90 mentioned in the present patent application are values relating to volume; the d50 value signifies the value of 50% of the drop population by volume.
For the purpose of the invention, the tenn "oil-in-water emulsion" is intended to mean a dispersion of an oily phase in an aqueous phase which may consist either of water or of a saline solution, that is optionally buffered. According to a particular embodiment of the invention, the aqueous phase of the emulsion consists of a buffer, such as Dulbecco's phosphate buffered solutions (D-PBS, without calcium or magnesium).
The term "adjuvant emulsion" is intended to mean an immunoadjuvant emulsion, i.e.
an emulsion capable of modifying the response of the immune system induced during the administration of an antigen, compared with the response obtained in the absence of the emulsion; this inunune system response may be reflected by antibody production or by activation of certain cells, in particular antigen-presenting cells (for example, dendritic cells), T lymphocytes and B lymphocytes. This cellular activation can be demonstrated by the presence of activation markers at the surface of the cells or by the release of cytokines. The modification of the immune response induced by the adjuvant emulsion may be quantitative in nature, i.e. an increase in the induced response is obtained, or qualitative in nature, i.e. a response that is different in nature or has a different orientation is obtained, or else an additional response is obtained.
The term "adjuvant emulsion" is also intended to mean an emulsion that makes it possible to reduce the amount of antigens administered for the same induced response.
For the purpose of the present invention, the term "immunogenic composition"
is intended to mean a composition comprising at least one antigen and that can be administered to humans or to animals in order to induce an immune system response.
This response may be a humoral response (antibody production) or a cellular response (proliferation and/or activation of immune cells). The immunogenic composition may be a composition for prophylactic purposes or for therapeutic purposes, or else both.
The immunogenic composition obtained according to the invention can be administered via any of the routes normally used or recommended for vaccines:
parenterally or mucosally, and can be in various forms, in particular a liquid or lyophilized form. It can be administered by means of a syringe or by means of a needle-free injector for intramuscular, subcutaneous or intradermal injection, or by means of a nasal spray.
For the purpose of the present invention, the term "antigen" is intended to mean any antigen that can be used in a vaccine, whether it involves a whole microorganism or a subunit antigen, regardless of its nature; the antigen may in fact be a peptide, a protein, a glycoprotein, a polysaccharide, a glycolipid, a lipopeptide, etc.
The adjuvant emulsion according to the invention is particularly suitable for viral antigens; particularly good results have in fact been obtained with antigens of the human cytomegalovirus, of the human immunodeficiency virus, and of the flu virus.
As regards the flu virus antigens, it is possible to use antigens that come from a single viral strain, or from a mixture of various strains. It is possible to use antigens derived from viruses cultured conventionally on eggs, or on cells. By means of the invention, it has been noted that whether for a single strain or for a mixture of strains, it is possible to obtain a satisfactory response of the immune system while at the same time very substantially reducing the amount of antigens present in the vaccine dose.
This may be of particularly great value in the case of the preparation of a vaccine against a flu pandemic, where it must be possible to produce, in a very short period of time, very large amounts of vaccine doses.
According to the invention, the oil-in-water emulsion comprises squalene, which is an oil initially originating from shark liver; it is an oil whose empirical chemical formula is C30H50, comprising 6 double bonds; this oil is metabolizable and has qualities that allow it to be used in an injectable pharmaceutical product. Squalene of plant origin, extracted from olive oil, also exists. Good results have in particular been obtained using the squalene provided by the company Fluka, which is of animal origin.
The amounts of squalene used for the preparation of a concentrated emulsion are advantageously between 5 and 45%; this concentrated emulsion is subsequently diluted during the preparation of immunogenic compositions so as to prepare immunizing doses in which the amount of squalene is between 0.5 and 5%. This dilution can be carried out by simply mixing the adjuvant emulsion according to the invention and the suspension comprising the antigen.
According to the invention, the emulsion comprises a nonionic hydrophilic surfactant, the value of the hydrophilic/lipophilic balance or HLB of which is greater than or equal to 10 and which belongs to the chemical group of polyoxyethylene alkyl ethers (PAEs), also known as polyoxyethylenated fatty alcohol ethers, or n-alkyl polyoxyethylene glycol ethers. These nonionic surfactants are obtained by chemical condensation between a fatty alcohol and ethylene oxide. They have a general chemical formula of the type CH3(CH2)X-(O-CHZ-CH2)õOH in which n denotes the number of ethylene oxide units and is usually between 10 and 60, and x + 1 is the carbon number, depending on the fatty alcohols used. In general, these products are mixtures of polymers with hydrocarbon-based chains of similar length.
The emulsion according to the invention usually comprises a single hydrophilic PAE.
A mixture of several PAEs is also suitable insofar as the overall HLB value is _ 10.
The polyoxyethylenated fatty alcohol ethers suitable for the subject of the invention can be in a liquid or solid form at ambient temperature. Among the solid compounds, preference is given to those which dissolve directly in the aqueous phase or which do not require substantial heating.
Insofar as the number of ethylene oxide units is sufficient, the polyoxyethylenated ethers of lauryl, myristyl, cetyl, oleyl and/or stearyl alcohols are particularly suitable for the subject of the invention. They can in particular be found in the range of products known under the trade names Brij for the products sold by the company ICI America's Inc., Eumulgin for the products sold by the company Cognis, or Simulsol for the products sold by the company SEPPIC.
A particularly preferred emulsion according to the invention contains, as nonionic hydrophilic surfactant, a polyoxyethylene alkyl ether chosen from the group consisting of ceteareth-12 (sold under the name Eumulgin B1), ceteareth-20 (Eumulgin(R B2), steareth-21 (Eumulgin0 S21), ceteth-20 (Simulsol(D 58 or BrijO 58), ceteth-10 (BrijO 56), steareth-10 (Brij(V 76), steareth-20 (Brij(D
78), oleth-10 (BrijO 96 or Brij(D 97) and oleth-20 (BrijO 98 or BrijO 99). The number assigned to each chemical name corresponds to the number of ethylene oxide units in the chemical formula.
Good results have been obtained with the product BrijO 56. A compound that is particularly suitable and preferred due to its semisynthetic origin is the polyoxy-ethylene (12) cetostearyl ether supplied by the company Cognis under the name EumulginT"'B1. This compound is a mixture of CH3(CH2)15-(O-CH2-CH2)12-OH and of CH3(CH2)17-(O-CH2-CH2)12-OH.
According to the invention, the adjuvant emulsion also comprises a hydrophobic nonionic surfactant; it must be a surfactant that can be used in the pharmaceutical industry; among surfactants that are suitable in this regard, mention may be made of sorbitan esters and mannide esters; the sorbitan esters are obtained by reaction of a fatty acid and of a mixture of partial esters of sorbitol and its mono- and dianhydrides;
this may involve a mono-, a di- or a triester, or even a mixture; they are hydrophobic surfactants for which the overall hydrophilic-lipophilic balance (HLB), is less than 9, and preferably less than 6. They can be found in particular in the range of surfactants sold by the company ICI Americas Inc. under the name Span , or by the company Cognis under the name DehymulsTM, or by the company ICI under the name ArlacelTM; as examples of surfactants that are particularly suitable, mention may be made of the sorbitan monooleate sold under the name Dehymuls SMOTM or Span 80.
Among the surfactants consisting of mannide esters, mention may be made of the mannide monooleate sold by the company Sigma, or by the company Seppic under the name Montanide 80TM
By virtue of the selection of these specific surfactants among all the surfactants proposed in the prior art for preparing emulsions, it has now been found that it is possible, very advantageously, to produce an oil-in-water adjuvant emulsion using a phase-inversion process.
For this, the amounts of squalene and of each of the surfactants used are advantageously chosen so as to obtain a mixture, the phase diagram of which comprises a zero mean curvature phase (microemulsion or lamellar phase type) for which the interfacial tensions are extremely low.
In the case of the use of squalene, it has been noted that the emulsions obtained are stable and monodisperse, with the oil droplets being very small in size (d90 less than 200 nm), when the overall HLB value of the various surfactants used is between 8.5 and 10, and more particularly between 8.6 and 9.6. To determine the respective concentrations of hydrophilic and hydrophobic surfactants in the composition of the emulsion, the following formula can be used:
HLB,t, = (HLBe X M) + HLBpae (1-M) in which, HLB,,, corresponds to the HLB of the mixture, which is preferably between 8.5 and 10, and more particularly between 8.6 and 9.6, HLBe corresponds to the HLB of the hydrophobic surfactant, M corresponds to the percentage by mass of the hydrophobic surfactant in the mixture consisting of the hydrophobic surfactant and the polyoxyethylene alkyl ether (PAE), HLBpae corresponds to the HLB of the PAE.
It has been noted that, by using a concentration of squalene of between 5 and 45%, an emulsion whose phase-inversion temperature is less than 95 C is very advantageously obtained.
For such an emulsion, it is possible to use a polyoxyethylene alkyl ether at a concentration of between 0.9 and 9% and a hydrophobic nonionic surfactant at a concentration of between 0.7 and 7%; the remainder of the emulsion consisting of an aqueous solvent.
According to a particular embodiment of the invention, the immunogenic composition also comprises an alditol such as, in particular, glycerol, erythritol, xylitol, sorbitol or mannitol. Good results have in particular been obtained with the mannitol sold by the company Roquette Freres. The amounts of alditol used in the preparation process can range between 1 and 10%, and more particularly between 2 and 7.
According to a particular embodiment of the invention, the adjuvant emulsion also comprises a cryoprotective agent which makes it possible to lyophilize the emulsion obtained; among the cryoprotective agents, sugars are particularly preferred, and especially sucrose. In addition, the emulsion according to the invention can comprise an alkylpolyglycoside, which is a surfactant with a sugar head; it may in particular be sodium decyl-D-galactoside uronate, or, according to a preferred embodiment, dodecyl-(3-maltoside available from the company Roche.
By virtue of the process for preparing the emulsion according to the invention by phase inversion obtained by varying the temperature, an oil-in-water emulsion, the size of the oil droplets of which is very homogeneous, is very readily and very reproducibly obtained: the d90 value (by volume) is less than 200 nm, preferably less than 150 nm, and even close to 100 nm while the d50 value is less than 100 nm, or even 90 nm. Most of the emulsions prepared according to the process of the invention have made it possible to attain d50 values of around 80 nm, with d90 values of around 100 nm (measurements carried out with a Coulter LS230). It is thus possible to perform a sterilizing filtration of the emulsion obtained, on the condition that the latter is sufficiently diluted.
Such emulsions in which the size of the drops is homogeneous and very small are stable over time. It has thus been possible to note that an emulsion prepared according to the invention and stored at 4 C, conserved, after 2 years, a monodisperse profile with a d50 value of 90 nm and a d90 value of 116 nm, which proves that the emulsion is very highly stable.
The size of the drops can be measured by various means, and in particular by LASER
diffraction particle sizes, such as the Beckman Coulter devices of the LS
range (in particular the LS230) or Malvern devices of the Mastersizer range (the Mastersizer 2000 in particular). The principle of measurement of these devices is based on analyzing the intensity of the light scattered by the particles as a function of the angle (large, medium and small angle detectors) when the sample is illuminated by a LASER beam. This analysis is carried out by means of mathematical models chosen according to the size and the nature of the material used. In the case of the measurement of the size of submicronic particles, it is necessary to apply a specific optical model (Mie theory) taking into account the refractive indices of the sample (here, 1.495 for squalene) and of its medium (here, 1.332 for water); it is also necessary to be capable of detecting the weak intensities emitted by the very fine particles, which requires an optimization of the analysis:
- an additional detection cell for the large-angle polarized intensity differential scattering measurement (PIDS system from Coulter, which allows measurement from 40 nm), - a detection system combining 2 wavelengths, blue and red light, from Malvern. The source of blue light of shorter wavelength, associated with wide-angle scattering and backscattering detectors, reinforces the performance levels of the analysis in the submicronic range.
According to the devices used, the measurements may vary slightly as a function of the components of the device and of the data processing software used. Thus, the same emulsion according to the invention was analyzed with the 2 devices and gave the following results:
- using the LS230, with the following parameters: IR particle = 1.495; IR
medium = 1.332; absorption value = 0; d50 = 80-90 nm and d90 = 120-130nm;
- using the Mastersizer 2000, with the following parameters: IR particle =
1.495; IR medium = 1.332; absorption value = 0; obscuring = 4-7%; "general purpose" optical model; d50 = 90-100 nm and d90 = 140-150 nm.
The process according to the invention may be carried out in the following way: a concentrated crude oil-in-water emulsion is prepared by incorporation of the aqueous phase (buffer solution, to which alditol is optionally added, comprising the polyoxyethylene alkyl ether) into the oily phase (squalene and hydrophobic nonionic surfactant); or, conversely, by incorporation of the oily phase into the aqueous phase.
A noncalibrated oil-in-water emulsion is then obtained, which rapidly manifests its instability. This emulsion is stirred and heated until a phase inversion is obtained, i.e.
a water-in-oil emulsion is obtained. The phase inversion or transition can be monitored by conductimetry. In fact, during the rise in temperature, the conductivity increases until phase inversion occurs; at this time, a relatively abrupt drop in conductivity is observed. The temperature at which the change in curvature of the curve for following the conductivity occurs reflects the passage from one type of emulsion to another; it is the phase inversion temperature. In reality, this temperature is rather a temperature range than a very precise point value; in fact, it may be considered that this temperature is a temperature determined to within 1 or 2 degrees so that the entire emulsion undergoes the phase inversion phenomenon. Once this phase inversion temperature has been reached, and therefore once in the presence of a water-in-oil emulsion, the heating is stopped and the mixture is cooled. The cooling can be carried out passively, by simply allowing the emulsion to return spontaneously to ambient temperature, or more actively, by immersing the emulsion, for example, in an ice bath. When the temperature passes through the phase inversion temperature, the water-in-oil emulsion will inverk again so as to once more give an oil-in-water emulsion, in which the size of the oil droplets is this time very homogeneous and small; the emulsion obtained is then very stable. It can be stored as it is, while awaiting dilution with a solution comprising the vaccine antigen.
This emulsion is thermoreversible, which means that, if it is again brought to a temperature above the phase inversion temperature, it will once again become a water-in-oil emulsion. It is noted that the curves for following the conductivity are superimposable for the same emulsion, irrespective of the number of thermoinversions undergone, and that the emulsions obtained always have the same particle size profile.
Advantageously according to the invention, the formulation of the emulsion is chosen so as to have a phase inversion temperature that is less than 95 C, and more particularly between 45 and 80 C, and more particularly still between 50 and 65 C.
This temperature range is advantageous since there is no risk of the emulsion changing state if it is stored at a relatively high temperature (= 37 C).
Furthermore, as in the process for preparing the thermoreversible emulsion, the heating of the components is not too severe, this contributes to maintaining the structural integrity of the components. When the phase-inversion temperature of the emulsion is high, in particular when it is greater than or in the region of 80 C, it may be useful to reduce it by adding to the composition of the emulsion an alditol, which is normally chosen from sorbitol, mannitol, glycerol, xylitol or erythritol. When the alditol is used in a concentration range of from 1 to 10% (w/w), and in particular in a concentration range of from 2 to 7% (w/w), the phase-inversion temperature of the emulsion is reduced by approximately 10 C., It is also possible to reduce the phase-inversion temperature of the emulsion by replacing the aqueous phase consisting only of water with a buffered saline aqueous phase. A Tris buffer, or a phosphate buffer such as PBS, or the Dulbecco PBS buffer without Ca2+ and without Mg2+, is normally used.
Alternatives to the process that has just been described exist. Specifically, it is possible, as has just been described, to mix the 2 aqueous and oily phases in order to obtain the crude emulsion which will then be heated and then cooled.
Alternatively, the 2 phases that have been prepared can be heated separately to a temperature slightly above the phase inversion temperature, before being mixed so as to give a water-in-oil inverse emulsion, which will be cooled until the oil-in-water submicronic emulsion is obtained.
It is also possible to slightly heat each of the phases before carrying out the mixing, which will result in an oil-in-water emulsion, and then to heat this emulsion to phase-inversion before carrying out the cooling.
All these operations can be carried out in separate containers for a batch preparation but it is also possible to use an on-line process.
The process for preparing the emulsion on-line may notably consist of a mixing, under hot conditions, of the two aqueous and oily phases prepared separately beforehand, through a thermostatted static mixer, followed by on-line cooling through a refrigerated heat exchanger connected at the outlet of the static mixer, and then final recovery of the emulsion according to the invention in an appropriate container (flask or reactor). A static mixer consisting of a succession of mixing elements made up of cross blades inclined relative to the axis of the tube into which they are introduced was successfully used. The energy required for the mixing is provided by the pumps that transport the fluids and the mixing is carried out without any mobile part, through the mixing elements by virtue of the separating, displacing and successive combining of the constituents of the mixture.
= CA 02613732 2007-12-28 The on-line production process is carried out in the following way: the aqueous phase (buffered solution comprising the polyoxyethylene alkyl ether) and the oily phase (squalene and hydrophobic nonionic surfactant) are prepared separately in two flasks or reactors. The two phases are heated with stirring to a temperature slightly above the phase inversion temperature. The two phases are then introduced into a thermostatted static mixer by means of 2 pumps, the flow rates of which are regulated so as to obtain the composition of the emulsion according to the invention. The water-in-oil inverse emulsion is obtained during the passage of the two phases in the static mixer.
The inverse emulsion is subsequently cooled by passing it on-line through a refrigerated heat exchanger connected at the outlet of the static mixer. The water-in-oil emulsion will then invert through the refrigerated heat exchanger to give an oil-in-water emulsion, which will be collected in a flask or reactor, and the characteristics of which are identical to those of the emulsion obtained by a batch process.
The adjuvant emulsion according to the invention is then used for the preparation of an immunogenic composition. A simple embodiment consists in mixing a solution comprising at least one vaccine antigen with an emulsion obtained according to one of the embodiments which have just been described. The immunogenic composition obtained is in the form of an oil-in-water emulsion or in the form of a thermoreversible oil-in-water emulsion when the amount of squalene represents at least 5% by mass of the total mass of the immunogenic composition.
Alternatively, it is possible to mix the antigen with the aqueous phase or with the oily phase before preparing the emulsion. Carrying out the process in such a manner implies, of course, that said antigens are antigens which are compatible with the thermoinversion process.
The solutions of the antigen may also contain mineral salts or one or more buffers, and also any other compound normally used in vaccines, such as stabilizers, preserving agents or, optionally, also other adjuvants.
For the preparation of a lyophilizable emulsion, a concentrated liquid emulsion is first of all prepared, as has just been described, but preferably choosing water rather than a buffered solution as aqueous phase, and then this emulsion is diluted with a solution comprising an alditol, a sugar and an alkylpolyglycoside, for example with a solution comprising mannitol, sucrose and dodecylmaltoside.
The emulsion obtained is tllen divided up into samples (for example, 0.5 ml) and subjected to a lyophilization cycle, which can be carried out in the following way:
- loading of the samples at +4 C, - approximately 2 hours of freezing at a set temperature of -45 C, - 14 to 19 hours of primary desiccation at a set temperature of 0 C, - 3 hour 30 min of secondary desiccation at a set temperature of + 25 C.
The emulsion obtained can then be conserved until it is used for the preparation of an immunogenic composition, i.e. until it is combined with a composition comprising vaccine antigens. This step for preparing the immunogenic composition can be carried out by taking up the lyophilized emulsion with an aqueous solution comprising the antigens. The immunogenic composition thus obtained can subsequently be conversed in the liquid state, or can be subjected to a further lyophilization cycle in order to be conserved in the form of a lyophilisate, if the nature of the antigens allows this.
Alternatively, it is possible to directly dilute the concentrated emulsion with an aqueous solution comprising both the vaccine antigens and also the alditol, the sugar and the alkylpolyglycoside, and to subsequently subject the composition obtained to the lyophilization. Such a manner of carrying out the process implies, of course, that the antigens are antigens that are compatible with a lyophilization process.
The following examples illustrate various embodiments of the invention.
Example 1: Preparation of an adjuvant emulsion according to the invention 3.71 g of EumulginTM B1 and 33.9 g of a 10% solution of mannitol in PBS buffer were mixed in a beaker, and the mixture was homogenized with stirring at approximately C.
30 In another container, 2.89 g of DehymulsTM SMO and 19.5 g of squalene were stirred magnetically.
= CA 02613732 2007-12-28 When homogeneous phases were obtained in each of the containers, the aqueous phase was incorporated into the oily phase, which was maintained at 30 C with stirring.
When the incorporation was complete, the crude emulsion obtained was heated until the temperature reached 58-60 C, while at the same time maintaining the stirring.
The heating was then stopped but the stirring was maintained until the temperature reached ambient temperature.
An oil-in-water emulsion was then obtained, the size of the oil droplets of which was centered around 80 nm (measurement carried out using an LS230), and the composition by mass of which was as follows:
- 32.5% of squalene, - 6.18% of polyoxyethylene (12) cetostearyl ether, - 4.82% of sorbitan monooleate, - 6% of mannitol.
Example 2: Vaccine composition against AIDS.
Vaccine compositions comprising a detoxified TAT III B protein as antigen were prepared. The TAT protein was detoxified by means of an alkylation reaction in an alkaline medium using iodoacetamide under the following conditions: number of micromoles of iodoacetamide = 200 X number of micromoles of TAT + number of micromoles of DTT. This detoxified protein and the process for preparing it are described in detail in application W099/33346, where it is identified under the term carboxymethylated TAT. This recombinant TAT antigen is conserved in solution, in the presence of 50 mM Tris buffer, pH 7.5, at -70 C.
The vaccine compositions to be administered were prepared from concentrated solutions, in order to obtain immunization doses of 200 l having the following quantitative compositions:
- for the composition having only the antigen: 20 g of TAT in 50 mM Tris buffer, 100 mM NaCI, at pH 7.5;
- for the composition according to the invention:
0 20 gg of TAT, = 5 mg of squalene = 0.75 mg of Dehymuls SMO, = 0.94 mg of Eumulgin Bl, = 0.91 mg of mannitol.
Two groups of six 8-week-old female BALB/c mice were provided, and were injected subcutaneously with one of the compositions prepared, in a proportion of one dose of 200 l per mouse; the injections were given on DO and on D21.
Blood samples were taken from the retroorbital sinus on D14 in order to assess the primary response and on D34 for the secondary response. The specific IgG 1 and IgG2a titers were determined by means of standardized ELISA assays.
The mice were sacrificed on D37; their spleen was removed and the splenocytes were isolated.
The results obtained regarding the humoral responses are summarized in the table below, in which the IgG titers are expressed in arbitrary ELISA units (log10).
For each group of mice, the value indicated in the table is the mean geometric titer of the values obtained for each of the mice.
In the case of the use of squalene, it has been noted that the emulsions obtained are stable and monodisperse, with the oil droplets being very small in size (d90 less than 200 nm), when the overall HLB value of the various surfactants used is between 8.5 and 10, and more particularly between 8.6 and 9.6. To determine the respective concentrations of hydrophilic and hydrophobic surfactants in the composition of the emulsion, the following formula can be used:
HLB,t, = (HLBe X M) + HLBpae (1-M) in which, HLB,,, corresponds to the HLB of the mixture, which is preferably between 8.5 and 10, and more particularly between 8.6 and 9.6, HLBe corresponds to the HLB of the hydrophobic surfactant, M corresponds to the percentage by mass of the hydrophobic surfactant in the mixture consisting of the hydrophobic surfactant and the polyoxyethylene alkyl ether (PAE), HLBpae corresponds to the HLB of the PAE.
It has been noted that, by using a concentration of squalene of between 5 and 45%, an emulsion whose phase-inversion temperature is less than 95 C is very advantageously obtained.
For such an emulsion, it is possible to use a polyoxyethylene alkyl ether at a concentration of between 0.9 and 9% and a hydrophobic nonionic surfactant at a concentration of between 0.7 and 7%; the remainder of the emulsion consisting of an aqueous solvent.
According to a particular embodiment of the invention, the immunogenic composition also comprises an alditol such as, in particular, glycerol, erythritol, xylitol, sorbitol or mannitol. Good results have in particular been obtained with the mannitol sold by the company Roquette Freres. The amounts of alditol used in the preparation process can range between 1 and 10%, and more particularly between 2 and 7.
According to a particular embodiment of the invention, the adjuvant emulsion also comprises a cryoprotective agent which makes it possible to lyophilize the emulsion obtained; among the cryoprotective agents, sugars are particularly preferred, and especially sucrose. In addition, the emulsion according to the invention can comprise an alkylpolyglycoside, which is a surfactant with a sugar head; it may in particular be sodium decyl-D-galactoside uronate, or, according to a preferred embodiment, dodecyl-(3-maltoside available from the company Roche.
By virtue of the process for preparing the emulsion according to the invention by phase inversion obtained by varying the temperature, an oil-in-water emulsion, the size of the oil droplets of which is very homogeneous, is very readily and very reproducibly obtained: the d90 value (by volume) is less than 200 nm, preferably less than 150 nm, and even close to 100 nm while the d50 value is less than 100 nm, or even 90 nm. Most of the emulsions prepared according to the process of the invention have made it possible to attain d50 values of around 80 nm, with d90 values of around 100 nm (measurements carried out with a Coulter LS230). It is thus possible to perform a sterilizing filtration of the emulsion obtained, on the condition that the latter is sufficiently diluted.
Such emulsions in which the size of the drops is homogeneous and very small are stable over time. It has thus been possible to note that an emulsion prepared according to the invention and stored at 4 C, conserved, after 2 years, a monodisperse profile with a d50 value of 90 nm and a d90 value of 116 nm, which proves that the emulsion is very highly stable.
The size of the drops can be measured by various means, and in particular by LASER
diffraction particle sizes, such as the Beckman Coulter devices of the LS
range (in particular the LS230) or Malvern devices of the Mastersizer range (the Mastersizer 2000 in particular). The principle of measurement of these devices is based on analyzing the intensity of the light scattered by the particles as a function of the angle (large, medium and small angle detectors) when the sample is illuminated by a LASER beam. This analysis is carried out by means of mathematical models chosen according to the size and the nature of the material used. In the case of the measurement of the size of submicronic particles, it is necessary to apply a specific optical model (Mie theory) taking into account the refractive indices of the sample (here, 1.495 for squalene) and of its medium (here, 1.332 for water); it is also necessary to be capable of detecting the weak intensities emitted by the very fine particles, which requires an optimization of the analysis:
- an additional detection cell for the large-angle polarized intensity differential scattering measurement (PIDS system from Coulter, which allows measurement from 40 nm), - a detection system combining 2 wavelengths, blue and red light, from Malvern. The source of blue light of shorter wavelength, associated with wide-angle scattering and backscattering detectors, reinforces the performance levels of the analysis in the submicronic range.
According to the devices used, the measurements may vary slightly as a function of the components of the device and of the data processing software used. Thus, the same emulsion according to the invention was analyzed with the 2 devices and gave the following results:
- using the LS230, with the following parameters: IR particle = 1.495; IR
medium = 1.332; absorption value = 0; d50 = 80-90 nm and d90 = 120-130nm;
- using the Mastersizer 2000, with the following parameters: IR particle =
1.495; IR medium = 1.332; absorption value = 0; obscuring = 4-7%; "general purpose" optical model; d50 = 90-100 nm and d90 = 140-150 nm.
The process according to the invention may be carried out in the following way: a concentrated crude oil-in-water emulsion is prepared by incorporation of the aqueous phase (buffer solution, to which alditol is optionally added, comprising the polyoxyethylene alkyl ether) into the oily phase (squalene and hydrophobic nonionic surfactant); or, conversely, by incorporation of the oily phase into the aqueous phase.
A noncalibrated oil-in-water emulsion is then obtained, which rapidly manifests its instability. This emulsion is stirred and heated until a phase inversion is obtained, i.e.
a water-in-oil emulsion is obtained. The phase inversion or transition can be monitored by conductimetry. In fact, during the rise in temperature, the conductivity increases until phase inversion occurs; at this time, a relatively abrupt drop in conductivity is observed. The temperature at which the change in curvature of the curve for following the conductivity occurs reflects the passage from one type of emulsion to another; it is the phase inversion temperature. In reality, this temperature is rather a temperature range than a very precise point value; in fact, it may be considered that this temperature is a temperature determined to within 1 or 2 degrees so that the entire emulsion undergoes the phase inversion phenomenon. Once this phase inversion temperature has been reached, and therefore once in the presence of a water-in-oil emulsion, the heating is stopped and the mixture is cooled. The cooling can be carried out passively, by simply allowing the emulsion to return spontaneously to ambient temperature, or more actively, by immersing the emulsion, for example, in an ice bath. When the temperature passes through the phase inversion temperature, the water-in-oil emulsion will inverk again so as to once more give an oil-in-water emulsion, in which the size of the oil droplets is this time very homogeneous and small; the emulsion obtained is then very stable. It can be stored as it is, while awaiting dilution with a solution comprising the vaccine antigen.
This emulsion is thermoreversible, which means that, if it is again brought to a temperature above the phase inversion temperature, it will once again become a water-in-oil emulsion. It is noted that the curves for following the conductivity are superimposable for the same emulsion, irrespective of the number of thermoinversions undergone, and that the emulsions obtained always have the same particle size profile.
Advantageously according to the invention, the formulation of the emulsion is chosen so as to have a phase inversion temperature that is less than 95 C, and more particularly between 45 and 80 C, and more particularly still between 50 and 65 C.
This temperature range is advantageous since there is no risk of the emulsion changing state if it is stored at a relatively high temperature (= 37 C).
Furthermore, as in the process for preparing the thermoreversible emulsion, the heating of the components is not too severe, this contributes to maintaining the structural integrity of the components. When the phase-inversion temperature of the emulsion is high, in particular when it is greater than or in the region of 80 C, it may be useful to reduce it by adding to the composition of the emulsion an alditol, which is normally chosen from sorbitol, mannitol, glycerol, xylitol or erythritol. When the alditol is used in a concentration range of from 1 to 10% (w/w), and in particular in a concentration range of from 2 to 7% (w/w), the phase-inversion temperature of the emulsion is reduced by approximately 10 C., It is also possible to reduce the phase-inversion temperature of the emulsion by replacing the aqueous phase consisting only of water with a buffered saline aqueous phase. A Tris buffer, or a phosphate buffer such as PBS, or the Dulbecco PBS buffer without Ca2+ and without Mg2+, is normally used.
Alternatives to the process that has just been described exist. Specifically, it is possible, as has just been described, to mix the 2 aqueous and oily phases in order to obtain the crude emulsion which will then be heated and then cooled.
Alternatively, the 2 phases that have been prepared can be heated separately to a temperature slightly above the phase inversion temperature, before being mixed so as to give a water-in-oil inverse emulsion, which will be cooled until the oil-in-water submicronic emulsion is obtained.
It is also possible to slightly heat each of the phases before carrying out the mixing, which will result in an oil-in-water emulsion, and then to heat this emulsion to phase-inversion before carrying out the cooling.
All these operations can be carried out in separate containers for a batch preparation but it is also possible to use an on-line process.
The process for preparing the emulsion on-line may notably consist of a mixing, under hot conditions, of the two aqueous and oily phases prepared separately beforehand, through a thermostatted static mixer, followed by on-line cooling through a refrigerated heat exchanger connected at the outlet of the static mixer, and then final recovery of the emulsion according to the invention in an appropriate container (flask or reactor). A static mixer consisting of a succession of mixing elements made up of cross blades inclined relative to the axis of the tube into which they are introduced was successfully used. The energy required for the mixing is provided by the pumps that transport the fluids and the mixing is carried out without any mobile part, through the mixing elements by virtue of the separating, displacing and successive combining of the constituents of the mixture.
= CA 02613732 2007-12-28 The on-line production process is carried out in the following way: the aqueous phase (buffered solution comprising the polyoxyethylene alkyl ether) and the oily phase (squalene and hydrophobic nonionic surfactant) are prepared separately in two flasks or reactors. The two phases are heated with stirring to a temperature slightly above the phase inversion temperature. The two phases are then introduced into a thermostatted static mixer by means of 2 pumps, the flow rates of which are regulated so as to obtain the composition of the emulsion according to the invention. The water-in-oil inverse emulsion is obtained during the passage of the two phases in the static mixer.
The inverse emulsion is subsequently cooled by passing it on-line through a refrigerated heat exchanger connected at the outlet of the static mixer. The water-in-oil emulsion will then invert through the refrigerated heat exchanger to give an oil-in-water emulsion, which will be collected in a flask or reactor, and the characteristics of which are identical to those of the emulsion obtained by a batch process.
The adjuvant emulsion according to the invention is then used for the preparation of an immunogenic composition. A simple embodiment consists in mixing a solution comprising at least one vaccine antigen with an emulsion obtained according to one of the embodiments which have just been described. The immunogenic composition obtained is in the form of an oil-in-water emulsion or in the form of a thermoreversible oil-in-water emulsion when the amount of squalene represents at least 5% by mass of the total mass of the immunogenic composition.
Alternatively, it is possible to mix the antigen with the aqueous phase or with the oily phase before preparing the emulsion. Carrying out the process in such a manner implies, of course, that said antigens are antigens which are compatible with the thermoinversion process.
The solutions of the antigen may also contain mineral salts or one or more buffers, and also any other compound normally used in vaccines, such as stabilizers, preserving agents or, optionally, also other adjuvants.
For the preparation of a lyophilizable emulsion, a concentrated liquid emulsion is first of all prepared, as has just been described, but preferably choosing water rather than a buffered solution as aqueous phase, and then this emulsion is diluted with a solution comprising an alditol, a sugar and an alkylpolyglycoside, for example with a solution comprising mannitol, sucrose and dodecylmaltoside.
The emulsion obtained is tllen divided up into samples (for example, 0.5 ml) and subjected to a lyophilization cycle, which can be carried out in the following way:
- loading of the samples at +4 C, - approximately 2 hours of freezing at a set temperature of -45 C, - 14 to 19 hours of primary desiccation at a set temperature of 0 C, - 3 hour 30 min of secondary desiccation at a set temperature of + 25 C.
The emulsion obtained can then be conserved until it is used for the preparation of an immunogenic composition, i.e. until it is combined with a composition comprising vaccine antigens. This step for preparing the immunogenic composition can be carried out by taking up the lyophilized emulsion with an aqueous solution comprising the antigens. The immunogenic composition thus obtained can subsequently be conversed in the liquid state, or can be subjected to a further lyophilization cycle in order to be conserved in the form of a lyophilisate, if the nature of the antigens allows this.
Alternatively, it is possible to directly dilute the concentrated emulsion with an aqueous solution comprising both the vaccine antigens and also the alditol, the sugar and the alkylpolyglycoside, and to subsequently subject the composition obtained to the lyophilization. Such a manner of carrying out the process implies, of course, that the antigens are antigens that are compatible with a lyophilization process.
The following examples illustrate various embodiments of the invention.
Example 1: Preparation of an adjuvant emulsion according to the invention 3.71 g of EumulginTM B1 and 33.9 g of a 10% solution of mannitol in PBS buffer were mixed in a beaker, and the mixture was homogenized with stirring at approximately C.
30 In another container, 2.89 g of DehymulsTM SMO and 19.5 g of squalene were stirred magnetically.
= CA 02613732 2007-12-28 When homogeneous phases were obtained in each of the containers, the aqueous phase was incorporated into the oily phase, which was maintained at 30 C with stirring.
When the incorporation was complete, the crude emulsion obtained was heated until the temperature reached 58-60 C, while at the same time maintaining the stirring.
The heating was then stopped but the stirring was maintained until the temperature reached ambient temperature.
An oil-in-water emulsion was then obtained, the size of the oil droplets of which was centered around 80 nm (measurement carried out using an LS230), and the composition by mass of which was as follows:
- 32.5% of squalene, - 6.18% of polyoxyethylene (12) cetostearyl ether, - 4.82% of sorbitan monooleate, - 6% of mannitol.
Example 2: Vaccine composition against AIDS.
Vaccine compositions comprising a detoxified TAT III B protein as antigen were prepared. The TAT protein was detoxified by means of an alkylation reaction in an alkaline medium using iodoacetamide under the following conditions: number of micromoles of iodoacetamide = 200 X number of micromoles of TAT + number of micromoles of DTT. This detoxified protein and the process for preparing it are described in detail in application W099/33346, where it is identified under the term carboxymethylated TAT. This recombinant TAT antigen is conserved in solution, in the presence of 50 mM Tris buffer, pH 7.5, at -70 C.
The vaccine compositions to be administered were prepared from concentrated solutions, in order to obtain immunization doses of 200 l having the following quantitative compositions:
- for the composition having only the antigen: 20 g of TAT in 50 mM Tris buffer, 100 mM NaCI, at pH 7.5;
- for the composition according to the invention:
0 20 gg of TAT, = 5 mg of squalene = 0.75 mg of Dehymuls SMO, = 0.94 mg of Eumulgin Bl, = 0.91 mg of mannitol.
Two groups of six 8-week-old female BALB/c mice were provided, and were injected subcutaneously with one of the compositions prepared, in a proportion of one dose of 200 l per mouse; the injections were given on DO and on D21.
Blood samples were taken from the retroorbital sinus on D14 in order to assess the primary response and on D34 for the secondary response. The specific IgG 1 and IgG2a titers were determined by means of standardized ELISA assays.
The mice were sacrificed on D37; their spleen was removed and the splenocytes were isolated.
The results obtained regarding the humoral responses are summarized in the table below, in which the IgG titers are expressed in arbitrary ELISA units (log10).
For each group of mice, the value indicated in the table is the mean geometric titer of the values obtained for each of the mice.
Vaccine IgGI IgG2a IgGI IgG2a IgGl/IgG2a ratio composition at D14 at D14 at D34 at D34 at D34 Tat 2.6 1.2 4.4 3.0 25 Tat+ PIT 3.5 2.5 5.7 5.0 5 The results obtained show that the emulsion according to the invention makes it possible to increase, overall, the humoral response and also tends to promote the type 1 T-helper response since the IgG2a response is increased more than the IgGl response.
As regards the cellular response, it was possible to demonstrate, by ELISPOT
assay after restimulation of the splenocytes removed with the recombinant TAT
protein, a clear increase in the number of cells producing y interferon when the splenocytes came from mice immunized with a preparation according to the invention (486 spots per 106 cells versus 39 per 106 for the preparation containing the antigen alone).
Similarly, the assaying of the cytokines in the culture supernatants showed the greater secretion of both y interferon (5028 pg/ml versus 1940 pg/mi) and Interleukin (5365 pg/ml versus 2394 pg/ml).
Example 3: Preparation of a vaccine composition against human c omegalovirus infections.
Vaccine compositions comprising, as vaccine antigen, a recombinant protein derived from an envelope glycoprotein of the Cytomegalovirus (CMV) Towne strain, called gB, the nucleotide and protein sequences of which are described in patent USP
5,834,307, were prepared. This recombinant protein is produced by a recombinant CHO line transfected with a plasmid called pPRgB27clv4 which contains a modified gB gene. Specifically, in order to facilitate the production of this recombinant protein by the CHO line, the gB gene was modified beforehand by deleting the part of the gene that encodes the transmembrane region of the gB protein corresponding to the amino acid sequence between Valine 677 and Arginine 752 and by introducing 3 point mutations such that the cleavage site that exists in the native gB was eliminated.
In fact, the recombinant protein produced by the recombinant CHO line corresponds to a truncated gB protein devoid of cleavage site and of transmembrane region, called gBdTM.
The construction of the plasmid pPRgB27clv4 and the production of the truncated gB
protein (gBdTM) by the recombinant CHO line are described in US 6,100,064. The purification of the truncated gB protein is carried out on an immunoaffinity chromatographic column using the monoclonal antibody 15D8 described by Rasmussen L. et al. ( J. Virol. (1985) 55: 274-280).
From a stock composition at 0.975 mg/mi of gB antigen thus obtained and maintained in phosphate buffer, the emulsion according to the invention concentrated as described in example 1, and an emulsion of the prior art obtained by microfluidization, 50 l doses of immunizing compositions were prepared, having the following compositions:
- 2 g of gB in citrate buffer at pH 6 (group called gB alone), - 2 gg of gB; 1.075 mg of squalene; 0.133 mg of MontaneTM VG 85 and 0.125 mg of TweenTM80 in citrate buffer at pH 6 (group called with emulsion of the prior art>>), - 2 g of gB; 1.25 mg of squalene; 0.185 mg of Dehymuls SMO; 0.235 mg of EumulginTM B1 and 0.23 0 mg of mannitol in PBS buffer at pH 7.4 (group called with emulsion of the invention>>).
Three groups of ten 8-week-old female Outbred OF1 mice were provided and were immunized twice, on DO and on D2 1, subcutaneously, with one of the compositions indicated above (each group of mice is given the same composition both times).
Blood samples were taken from the retroorbital sinus on D20 and D34 and were used to determine the concentrations of IgGI- and IgG2a-type antibodies specific for the gB antigen.
The assays were carried out by means of ELISA assays; the results obtained are given in the table below, and are expressed as log] o of the ELISA titers. The values indicated are the mean values obtained for each group of mice.
As regards the cellular response, it was possible to demonstrate, by ELISPOT
assay after restimulation of the splenocytes removed with the recombinant TAT
protein, a clear increase in the number of cells producing y interferon when the splenocytes came from mice immunized with a preparation according to the invention (486 spots per 106 cells versus 39 per 106 for the preparation containing the antigen alone).
Similarly, the assaying of the cytokines in the culture supernatants showed the greater secretion of both y interferon (5028 pg/ml versus 1940 pg/mi) and Interleukin (5365 pg/ml versus 2394 pg/ml).
Example 3: Preparation of a vaccine composition against human c omegalovirus infections.
Vaccine compositions comprising, as vaccine antigen, a recombinant protein derived from an envelope glycoprotein of the Cytomegalovirus (CMV) Towne strain, called gB, the nucleotide and protein sequences of which are described in patent USP
5,834,307, were prepared. This recombinant protein is produced by a recombinant CHO line transfected with a plasmid called pPRgB27clv4 which contains a modified gB gene. Specifically, in order to facilitate the production of this recombinant protein by the CHO line, the gB gene was modified beforehand by deleting the part of the gene that encodes the transmembrane region of the gB protein corresponding to the amino acid sequence between Valine 677 and Arginine 752 and by introducing 3 point mutations such that the cleavage site that exists in the native gB was eliminated.
In fact, the recombinant protein produced by the recombinant CHO line corresponds to a truncated gB protein devoid of cleavage site and of transmembrane region, called gBdTM.
The construction of the plasmid pPRgB27clv4 and the production of the truncated gB
protein (gBdTM) by the recombinant CHO line are described in US 6,100,064. The purification of the truncated gB protein is carried out on an immunoaffinity chromatographic column using the monoclonal antibody 15D8 described by Rasmussen L. et al. ( J. Virol. (1985) 55: 274-280).
From a stock composition at 0.975 mg/mi of gB antigen thus obtained and maintained in phosphate buffer, the emulsion according to the invention concentrated as described in example 1, and an emulsion of the prior art obtained by microfluidization, 50 l doses of immunizing compositions were prepared, having the following compositions:
- 2 g of gB in citrate buffer at pH 6 (group called gB alone), - 2 gg of gB; 1.075 mg of squalene; 0.133 mg of MontaneTM VG 85 and 0.125 mg of TweenTM80 in citrate buffer at pH 6 (group called with emulsion of the prior art>>), - 2 g of gB; 1.25 mg of squalene; 0.185 mg of Dehymuls SMO; 0.235 mg of EumulginTM B1 and 0.23 0 mg of mannitol in PBS buffer at pH 7.4 (group called with emulsion of the invention>>).
Three groups of ten 8-week-old female Outbred OF1 mice were provided and were immunized twice, on DO and on D2 1, subcutaneously, with one of the compositions indicated above (each group of mice is given the same composition both times).
Blood samples were taken from the retroorbital sinus on D20 and D34 and were used to determine the concentrations of IgGI- and IgG2a-type antibodies specific for the gB antigen.
The assays were carried out by means of ELISA assays; the results obtained are given in the table below, and are expressed as log] o of the ELISA titers. The values indicated are the mean values obtained for each group of mice.
D20 D34 IgGl/IgG2a Nature of the groups IgGI IgG2a IgGl IgG2a ratio at D34 gB alone 2.474 2.094 3.801 2.941 137 gB + emulsion of the prior art 4.063 2.980 5.493 4.185 143 gB + emulsion according to the 4.615 3.914 5.615 4.854 14 invention These results show the effectiveness of the emulsion according to the invention, which allowed a greater induction of antibodies, both those of IgGl type and of IgG2a type, with, in addition, compared with the emulsion according to the prior art, the obtaining of the desired result in the context of a vaccine against human cytomegalovirus, which is that of orienting the immune response toward a TH1 response (an indicator of which is the IgG2a titer), while at the same time maintaining the TH2-type response (an indicator of which is the IgGl titer) at a sufficient level.
Example 4: Vaccine composition against the flu.
Flu virus antigens were available, obtained according to the process described in the examples of application WO 96/05294, with the exception of the fact that the viral strain used was the A/New Caledonia H1N1 strain.
Using this preparation of antigens, the concentrated emulsion according to the invention obtained in example 1, and a suspension of aluminum provided by REHEIS
under the name AIOOH Rehydra, 50 l immunization doses were prepared, which doses had the composition indicated hereinafter, in which the amounts of flu antigens are expressed by weight of herpagglutinin HA:
- either 1 g of HA in PBS buffer, - or 5 g of HA in PBS buffer, - or 1 g of HA and 60 gg of aluminum hydroxide, - or 1 gg of HA; 1.25 mg of squalene; 0.185 mg of DehymulsTM SMO; 0.235 mg of EumulginTM B; 0.21 mg of mannitol; the entire mixture in PBS buffer.
Example 4: Vaccine composition against the flu.
Flu virus antigens were available, obtained according to the process described in the examples of application WO 96/05294, with the exception of the fact that the viral strain used was the A/New Caledonia H1N1 strain.
Using this preparation of antigens, the concentrated emulsion according to the invention obtained in example 1, and a suspension of aluminum provided by REHEIS
under the name AIOOH Rehydra, 50 l immunization doses were prepared, which doses had the composition indicated hereinafter, in which the amounts of flu antigens are expressed by weight of herpagglutinin HA:
- either 1 g of HA in PBS buffer, - or 5 g of HA in PBS buffer, - or 1 g of HA and 60 gg of aluminum hydroxide, - or 1 gg of HA; 1.25 mg of squalene; 0.185 mg of DehymulsTM SMO; 0.235 mg of EumulginTM B; 0.21 mg of mannitol; the entire mixture in PBS buffer.
Eight groups of five 8-week-old female BALB/c mice were provided and were administered, on DO, with the compositions prepared according to the following distribution:
- one group received the composition having 1 jig of HA, subcutaneously, - one group received the same composition having 1 g of HA, intradermally, - one group received the composition having 5 g of HA, subcutaneously, - one group received the same composition having 5 g of HA, intradermally, - one group received the composition having I g of HA and 60 gg of aluminum, subcutaneously, - one group received the same composition having 1 g of HA and 60 gg of aluminum, intradermally, - one group received the composition having 1 gg of HA and the emulsion according to the invention, subcutaneously, - one group received the composition having 1 g of HA and the emulsion according to the invention, intradennally.
Blood samples were taken from each of the mice on D14, D28, D41, D56 and D105.
The sera from the immunized mice were assayed, firstly, by the ELISA technique in order to evaluate their content of total antibodies induced against the flu strain A/H1N1 of the trivalent vaccine (the antibody titers are expressed as the log10 value of arbitrary ELISA units, with a detection threshold of 1.3 log10) and, secondly, by the HAI (hemaglutination inhibition) technique in order to determine their content of functional antibodies against the flu strain A/HIN1. The antibody titers are expressed as the inverse of the dilution in arithmetic value, with a detection threshold at 5.
The results obtained are reiterated in the tables hereinafter, in which the values indicated represent the mean of the titers of the mice of each group.
- one group received the composition having 1 jig of HA, subcutaneously, - one group received the same composition having 1 g of HA, intradermally, - one group received the composition having 5 g of HA, subcutaneously, - one group received the same composition having 5 g of HA, intradermally, - one group received the composition having I g of HA and 60 gg of aluminum, subcutaneously, - one group received the same composition having 1 g of HA and 60 gg of aluminum, intradermally, - one group received the composition having 1 gg of HA and the emulsion according to the invention, subcutaneously, - one group received the composition having 1 g of HA and the emulsion according to the invention, intradennally.
Blood samples were taken from each of the mice on D14, D28, D41, D56 and D105.
The sera from the immunized mice were assayed, firstly, by the ELISA technique in order to evaluate their content of total antibodies induced against the flu strain A/H1N1 of the trivalent vaccine (the antibody titers are expressed as the log10 value of arbitrary ELISA units, with a detection threshold of 1.3 log10) and, secondly, by the HAI (hemaglutination inhibition) technique in order to determine their content of functional antibodies against the flu strain A/HIN1. The antibody titers are expressed as the inverse of the dilution in arithmetic value, with a detection threshold at 5.
The results obtained are reiterated in the tables hereinafter, in which the values indicated represent the mean of the titers of the mice of each group.
ELISA titers:
Group of Immunization D14 D28 D41 D56 D105 mice route HA 1 gg subcutaneous 2.838 3.288 3.556 3.581 3.535 HA 5 g subcutaneous 3.203 3.642 3.836 3.732 3.844 HA 1 g + subcutaneous 2.860 3.363 3.843 3.951 3.982 AIOOH
HA 1 g + subcutaneous 4.043 4.511 4.753 4.723 4.681 emulsion HA 1 g intradermal 2.174 2.814 3.143 3.075 2.735 HA 5 g intradermal 2.839 3.297 3.496 3.549 3.479 HA 1 g + intradermal 2.654 3.004 3.137 3.020 2.724 AIOOH
HA 1 g + intradermal 4.134 4.692 4.895 4.911 4.823 emulsion HAI titers:
Group of Immunization D14 D28 D41 D56 D105 mice route HA I g subcutaneous 5 6 5 40 23 HA 5 gg subcutaneous 5 9 20 HA 1 g + subcutaneous 5 15 23 121 160 HA 1 g + subcutaneous 6 160 368 422 485 emulsion HA 1 g intradermal 5 5 5 23 8 HA 5 g intradermal 5 8 10 HA 1 g + intradermal 5 5 5 26 7 AIOOH
HA 1 g + intradermal 7 557 1640 1557 1844 emulsion These results show the advantage of the present invention; specifically, aluminum hydroxide, which is a well known adjuvant widely used in the prior art, did not make it possible to increase the immunogenicity of the flu antigens with the same rapidity and the same strength as the formulation according to the invention; it is also noted that the composition according to the invention was particularly effective, whether given subcutaneously or intraderrnally.
Example 5: Vaccine composition against the flu.
The intention was to evaluate, in mice, the advantage of the present invention for decreasing the amount of vaccine antigen when the vaccine involved is a vaccine against the flu which contains, as antigens, 3 flu virus strains and which would be administered intradermally.
To this end, the concentrated emulsion of example 1 was diluted with PBS
buffer in order to obtain a 5% squalene emulsion, which was further diluted by half with a composition comprising the antigens.
A composition comprising flu virus originating from 3 different viral strains obtained in the manner described in patent application WO 96/05294 was in fact available, the 3 strains being in this case the A/New Caledonia (H1N1) strain, the A/Wyoming (H3N2) strain and the B/Jiangsu strain. Such a trivalent vaccine composition is conventional for a flu vaccine and corresponds to the vaccine sold in the northern hemisphere during the 2004 flu campaign. The amounts of antigens of each of the viral strains are assessed through their amount of hemagglutinins HA.
The immunization doses prepared, having a volume of 50 l, had the compositions indicated below:
- 0.33 g of HA of each of the viral strains in PBS buffer at pH 7.4;
- 1.31 g of HA of each of the viral strains in PBS buffer at pH 7.4;
- 5.25 g of HA of each of the viral strains in PBS buffer at pH 7.4;
- 10.5 g of HA of each of the viral strains in PBS buffer at pH 7.4;
- 21 g of HA of each of the viral strains in PBS buffer at pH 7.4;
- 0.33 gg of HA of each of the viral strains; 1.25 mg of squalene; 0.185 mg of DehymulsTM SMO; 0.235 mg of EumulginTM B 1 and 0.230 mg of mannitol in PBS buffer at pH 7.4;
Group of Immunization D14 D28 D41 D56 D105 mice route HA 1 gg subcutaneous 2.838 3.288 3.556 3.581 3.535 HA 5 g subcutaneous 3.203 3.642 3.836 3.732 3.844 HA 1 g + subcutaneous 2.860 3.363 3.843 3.951 3.982 AIOOH
HA 1 g + subcutaneous 4.043 4.511 4.753 4.723 4.681 emulsion HA 1 g intradermal 2.174 2.814 3.143 3.075 2.735 HA 5 g intradermal 2.839 3.297 3.496 3.549 3.479 HA 1 g + intradermal 2.654 3.004 3.137 3.020 2.724 AIOOH
HA 1 g + intradermal 4.134 4.692 4.895 4.911 4.823 emulsion HAI titers:
Group of Immunization D14 D28 D41 D56 D105 mice route HA I g subcutaneous 5 6 5 40 23 HA 5 gg subcutaneous 5 9 20 HA 1 g + subcutaneous 5 15 23 121 160 HA 1 g + subcutaneous 6 160 368 422 485 emulsion HA 1 g intradermal 5 5 5 23 8 HA 5 g intradermal 5 8 10 HA 1 g + intradermal 5 5 5 26 7 AIOOH
HA 1 g + intradermal 7 557 1640 1557 1844 emulsion These results show the advantage of the present invention; specifically, aluminum hydroxide, which is a well known adjuvant widely used in the prior art, did not make it possible to increase the immunogenicity of the flu antigens with the same rapidity and the same strength as the formulation according to the invention; it is also noted that the composition according to the invention was particularly effective, whether given subcutaneously or intraderrnally.
Example 5: Vaccine composition against the flu.
The intention was to evaluate, in mice, the advantage of the present invention for decreasing the amount of vaccine antigen when the vaccine involved is a vaccine against the flu which contains, as antigens, 3 flu virus strains and which would be administered intradermally.
To this end, the concentrated emulsion of example 1 was diluted with PBS
buffer in order to obtain a 5% squalene emulsion, which was further diluted by half with a composition comprising the antigens.
A composition comprising flu virus originating from 3 different viral strains obtained in the manner described in patent application WO 96/05294 was in fact available, the 3 strains being in this case the A/New Caledonia (H1N1) strain, the A/Wyoming (H3N2) strain and the B/Jiangsu strain. Such a trivalent vaccine composition is conventional for a flu vaccine and corresponds to the vaccine sold in the northern hemisphere during the 2004 flu campaign. The amounts of antigens of each of the viral strains are assessed through their amount of hemagglutinins HA.
The immunization doses prepared, having a volume of 50 l, had the compositions indicated below:
- 0.33 g of HA of each of the viral strains in PBS buffer at pH 7.4;
- 1.31 g of HA of each of the viral strains in PBS buffer at pH 7.4;
- 5.25 g of HA of each of the viral strains in PBS buffer at pH 7.4;
- 10.5 g of HA of each of the viral strains in PBS buffer at pH 7.4;
- 21 g of HA of each of the viral strains in PBS buffer at pH 7.4;
- 0.33 gg of HA of each of the viral strains; 1.25 mg of squalene; 0.185 mg of DehymulsTM SMO; 0.235 mg of EumulginTM B 1 and 0.230 mg of mannitol in PBS buffer at pH 7.4;
- 1.31 gg of HA of each of the viral strains; 1.25 mg of squalene; 0.185 mg of DehymulsTM SMO; 0.235 mg of EumulginTM B 1 and 0.230 mg of mannitol in PBS buffer at pH 7.4;
- 5.25 g of HA of each of the viral strains; 1.25 mg of squalene; 0.185 mg of DehymulsTM SMO; 0.235 mg of EumulginTM B 1 and 0.230 mg of mannitol in PBS buffer at pH 7.4.
Eight groups of ten 6- to 8-week-old female BALB/c mice were provided and were administered intradermally (internal face of the ear) with one of the compositions prepared, at a rate of one composition per group.
Three weeks after immunization, blood samples were taken and, for each of the groups, the IgGs induced against each of the viral strains were assayed by ELISA; a hemagglutinin inhibition assay against each viral strain was also carried out for each of the groups.
The results obtained are represented in the table below in the form of means for each of the groups. The ELISA results are expressed as loglo of arbitrary units, and the HAI results are the mean arithmetic titers of the inverses of the dilutions.
Nature H1N1 H3N2 B
Composition ELISA HAI ELISA HAI ELISA HAI
0.33 g HA 3.51 35 4.38 243 4.28 25 1.31 g HA 3.96 65 4.74 640 4.35 32 5.25 g HA 4.16 92 5.05 970 4.62 53 10.5 gg HA 4.38 197 5.18 1810 4.71 130 21 g HA 4.63 260 5.37 2389 4.98 184 0.33 g HA 4.27 226 5.20 2389 4.91 149 + emulsion 1.31 g HA 4.46 279 5.37 3880 4.95 171 + emulsion 5.25 g HA 4.68 394 5.58 5487 5.12 22 + emulsion These results demonstrate the particular advantage of the invention for reducing the amount of antigens; specifically, by virtue of the emulsion according to the invention, it was possible, for the same immune response induced, to very substantially decrease the amount of antigens present in the immunization dose.
Example 6: Trivalent vaccine composition against the flu in a non-naive population The intention was to test the effectiveness of the emulsion of the invention in the case of a flu vaccine that would be administered to individuals whose body has already been in contact with flu virus antigens, as is frequently the case, either because the individuals have already been in contact with the flu virus, or because they have already been previously immunized with a flu vaccine.
According to the information published by C.W. Potter in Vaccine, 2003, 21:940-5, it is possible to use, as animal model for carrying out this test, BALB/c mice pre-immunized intramuscularly with a trivalent vaccine.
50 gl immunization doses comprising either PBS buffer only, or trivalent vaccine from the 2004 campaign, i.e. a vaccine comprising the A/New Caledonia (H1N1) strain, the A/Wyoming (H3N2) strain and the B/Jiangsu strain, in a proportion of 5 g of HA of each of the strains, in PBS buffer at pH 7.4, were therefore prepared.
Six groups of seven BALB/c mice were provided; 3 groups were immunized with the doses comprising only buffer, and 3 others with the trivalent vaccine, intramuscularly.
l immunization doses were also prepared from the concentrated emulsion of example 1 and a vaccine composition comprising the 3 viral strains of the 2004 campaign mentioned above, these immunization doses having the following 25 compositions:
- PBS buffer alone, - 0.3 g of HA of each of the viral strains in PBS buffer, - 0.3 g of HA of each of the viral strains; 0.75 mg of squalene; 0.11 mg of DehymulsTM SMO; 0.143 mg of EumulginTM B1 and 0.138 mg of mannitol in 30 PBS buffer at pH 7.4.
Each of the compositions thus prepared was used to immunize, on D34 intradermally (in the internal face of the ear), both a group of mice having previously received only PBS buffer, and a group of mice having received a dose of trivalent vaccine.
On D56, a blood sample was taken from each of the mice and the antibodies produced against the H1N1 strain (A/New Caledonia) were titered by means of a hemagglutinin inhibition assay.
The results obtained have been summarized in the table below and represent the mean values obtained for each group of mice having followed the same immunization protocol.
Mouse group Nature of the dose Nature of the dose for HAI titer with respect identification for the im priming the id boost to the H1N1 strain Trivalent vaccine B PBS containing 0.3 g 59 HA/strain Trivalent vaccine C PBS containing 0.3 g 320 HA/strain + emulsion D Trivalent vaccine containing 5 gg PBS 145 HA/strain E Trivalent vaccine Trivalent vaccine containing 5 g containing 0.3 g 476 HA/strain HA/strain F Trivalent vaccine Trivalent vaccine containing 5 g containing 0.3 g 861 HA/strain HA/strain + emulsion These results show how advantageous the invention is, even in individuals who are non-naive with respect to the antigen administered. In fact, contrary to the observations by C.W. Potter when using this model, who, himself, has only been able to show a weak adjuvant effect of Iscoms when they were used to immunize mice pre-infected or pre-immunized with flu antigens, here it is seen that the emulsion according to the invention made it possible to significantly increase the response induced, whether this was with naive mice or with mice having already been immunized with flu vaccine.
Example 7: Trivalent vaccine composition against the flu comprising low doses of antigens 30 l immunization doses were prepared from the concentrated emulsion of example 1 and a vaccine composition comprising the 3 viral strains of the 2004 campaign (the A/New Caledonia (HIN1) strain, the A/Wyoming (H3N2) strain and the B/Jiangsu strain), these immunization doses having the following compositions:
- 0.1 g of HA of each of the viral strains in PBS buffer, - 0.4 g of HA of each of the viral strains in PBS buffer, - 1.6 g of HA of each of the viral strains in PBS buffer, - 6.3 g of HA of each of the viral strains in PBS buffer, - 0.1 g of HA; 0.75 mg of squalene; 0.11 mg of DehyrnulsTM SMO; 0.143 mg of EumulginTM B1 and 0.138 mg of mannitol in PBS buffer at pH 7.4, - 0.4 g of HA; 0.75 mg of squalene; 0.11 mg of DehymulsTM SMO; 0.143 mg of EumulginTM B1 and 0.138 mg of mannitol in PBS buffer at pH 7.4.
Six groups of eight 8-week-old female BALB/c mice were provided and were administered, on DO, intradermally (internal face of the ear) with a dose of 30 l of one of the compositions indicated below (1 composition per group).
In each group, a 2nd dose having the same nature as the 1 st dose administered was again administered, intradermally, to half the mice on D29.
Blood samples were taken on D22 and on D43 in order to determine the amounts of antibodies induced.
The antibody titers were assayed by ELISA for the antibodies induced at D22 and at D43, with respect to all the strains administered: H1N1, H3N2 and B, and by HAI
with respect to the HIN1 strain only, both at D22 and at D43. The results obtained have been summarized in the table below, in which the titers expressed are the means obtained for each group of mice. As regards the results at D43, the means were determined separately within the same group, for the mice having received 2 doses of vaccine and those having received only one.
Vaccine H1N1 H3N2 B ELISA H1N1 HAI H1N1 HAI titer at composition ELISA titer ELISA titer at D22 titer at D22 D43 at D22 titer at D22 Boosted Non-mice boosted mice 0.1 g HA 3.467 4.131 4.063 57 95 80 0.4 gg HA 3.816 4.527 4.313 73 226 80 1.6 gg HA 4.069 4.831 4.750 147 1280 135 6.3 gg HA 4.534 5.298 4.947 320 1522 320 0.1 g HA
+ emulsion 4.200 5.015 4.807 207 2153 538 0.4 g HA
+ emulsion 4.612 5.482 5.001 453 2560 640 Vaccine H1N1 ELISA titer at H3N2 ELISA titer at B ELISA titer at D43 composition D43 D43 Boosted Non- Boosted Non- Boosted Non-mice boosted mice boosted mice boosted mice mice mice 0.1 g HA 3.833 3.425 4.782 4.174 4.479 3.911 0.4 g HA 4.385 3.599 5.250 4.354 5.053 4.079 1.6 pg HA 4.906 3.876 5.526 4.779 5.458 4.487 6.3 g HA 5.287 4.176 6.073 5.033 5.678 4.773 0.1 g HA 5.210 4.523 5.990 5.264 5.723 4.943 + emulsion 0.4 g HA 5.394 4.790 6.171 5.640 5.962 5.144 + emulsion These results show that, by virtue of the emulsion according to the invention, even with low doses of antigens, very substantial humoral responses were obtained.
Thus, it can be noted that the best results are those obtained with a dose of 0.4 gg of HA of each of the viral strains and an emulsion according to the invention; these results are, very surprisingly, much better than those obtained by using a dose of 6.3 gg of HA
alone. In addition, it is noted that, even in the individuals not given a booster dose, the immune system continues to induce antibodies, whereas this is not the case for the individuals given the non-adjuvanted vaccine antigens.
Example 8: Trivalent vaccine composition against the flu 30 l immunization doses were prepared from the concentrated emulsion of example 1 and a vaccine composition comprising the 3 viral strains of the 2004 campaign (the A/New Caledonia (H1N1) strain, the A/Wyoming (H3N2) strain and the B/Jiangsu strain), these immunization doses having the following compositions:
- 0.1 g of HA of each of the viral strains in PBS buffer, - 0.4 g of HA of each of the viral strains in PBS buffer, - 1.6 g of HA of each of the viral strains in PBS buffer, - 6.3 gg of HA of each of the viral strains in PBS buffer, - 0.1 gg of HA; 0.75 mg of squalene; 0.11 mg of DehymulsTM SMO; 0.143 mg of EumulginTM B1 and 0.138 mg of mannitol in PBS buffer at pH 7.4, - 0.4 g of HA; 0.75 mg of squalene; 0.11 mg of DehymulsTM SMO; 0.143 mg of EumulginTM B1 and 0.138 mg of mannitol in PBS buffer at pH 7.4.
Six groups of eight 8-week-old female C57BL/6J mice were provided and were administered, on DO intradermally (internal face of the ear), with a dose of 30 l of one of the compositions indicated above (1 composition per group).
Blood samples were taken on D23 in order to determine the amounts of antibodies induced.
The antibody titers were assayed by ELISA and by HAI for the antibodies induced with respect to all the strains administered: H1N1, H3N2 and B.
The results obtained have been summarized in the table below, in which the titers expressed are the means obtained for each group of mice.
- 5.25 g of HA of each of the viral strains; 1.25 mg of squalene; 0.185 mg of DehymulsTM SMO; 0.235 mg of EumulginTM B 1 and 0.230 mg of mannitol in PBS buffer at pH 7.4.
Eight groups of ten 6- to 8-week-old female BALB/c mice were provided and were administered intradermally (internal face of the ear) with one of the compositions prepared, at a rate of one composition per group.
Three weeks after immunization, blood samples were taken and, for each of the groups, the IgGs induced against each of the viral strains were assayed by ELISA; a hemagglutinin inhibition assay against each viral strain was also carried out for each of the groups.
The results obtained are represented in the table below in the form of means for each of the groups. The ELISA results are expressed as loglo of arbitrary units, and the HAI results are the mean arithmetic titers of the inverses of the dilutions.
Nature H1N1 H3N2 B
Composition ELISA HAI ELISA HAI ELISA HAI
0.33 g HA 3.51 35 4.38 243 4.28 25 1.31 g HA 3.96 65 4.74 640 4.35 32 5.25 g HA 4.16 92 5.05 970 4.62 53 10.5 gg HA 4.38 197 5.18 1810 4.71 130 21 g HA 4.63 260 5.37 2389 4.98 184 0.33 g HA 4.27 226 5.20 2389 4.91 149 + emulsion 1.31 g HA 4.46 279 5.37 3880 4.95 171 + emulsion 5.25 g HA 4.68 394 5.58 5487 5.12 22 + emulsion These results demonstrate the particular advantage of the invention for reducing the amount of antigens; specifically, by virtue of the emulsion according to the invention, it was possible, for the same immune response induced, to very substantially decrease the amount of antigens present in the immunization dose.
Example 6: Trivalent vaccine composition against the flu in a non-naive population The intention was to test the effectiveness of the emulsion of the invention in the case of a flu vaccine that would be administered to individuals whose body has already been in contact with flu virus antigens, as is frequently the case, either because the individuals have already been in contact with the flu virus, or because they have already been previously immunized with a flu vaccine.
According to the information published by C.W. Potter in Vaccine, 2003, 21:940-5, it is possible to use, as animal model for carrying out this test, BALB/c mice pre-immunized intramuscularly with a trivalent vaccine.
50 gl immunization doses comprising either PBS buffer only, or trivalent vaccine from the 2004 campaign, i.e. a vaccine comprising the A/New Caledonia (H1N1) strain, the A/Wyoming (H3N2) strain and the B/Jiangsu strain, in a proportion of 5 g of HA of each of the strains, in PBS buffer at pH 7.4, were therefore prepared.
Six groups of seven BALB/c mice were provided; 3 groups were immunized with the doses comprising only buffer, and 3 others with the trivalent vaccine, intramuscularly.
l immunization doses were also prepared from the concentrated emulsion of example 1 and a vaccine composition comprising the 3 viral strains of the 2004 campaign mentioned above, these immunization doses having the following 25 compositions:
- PBS buffer alone, - 0.3 g of HA of each of the viral strains in PBS buffer, - 0.3 g of HA of each of the viral strains; 0.75 mg of squalene; 0.11 mg of DehymulsTM SMO; 0.143 mg of EumulginTM B1 and 0.138 mg of mannitol in 30 PBS buffer at pH 7.4.
Each of the compositions thus prepared was used to immunize, on D34 intradermally (in the internal face of the ear), both a group of mice having previously received only PBS buffer, and a group of mice having received a dose of trivalent vaccine.
On D56, a blood sample was taken from each of the mice and the antibodies produced against the H1N1 strain (A/New Caledonia) were titered by means of a hemagglutinin inhibition assay.
The results obtained have been summarized in the table below and represent the mean values obtained for each group of mice having followed the same immunization protocol.
Mouse group Nature of the dose Nature of the dose for HAI titer with respect identification for the im priming the id boost to the H1N1 strain Trivalent vaccine B PBS containing 0.3 g 59 HA/strain Trivalent vaccine C PBS containing 0.3 g 320 HA/strain + emulsion D Trivalent vaccine containing 5 gg PBS 145 HA/strain E Trivalent vaccine Trivalent vaccine containing 5 g containing 0.3 g 476 HA/strain HA/strain F Trivalent vaccine Trivalent vaccine containing 5 g containing 0.3 g 861 HA/strain HA/strain + emulsion These results show how advantageous the invention is, even in individuals who are non-naive with respect to the antigen administered. In fact, contrary to the observations by C.W. Potter when using this model, who, himself, has only been able to show a weak adjuvant effect of Iscoms when they were used to immunize mice pre-infected or pre-immunized with flu antigens, here it is seen that the emulsion according to the invention made it possible to significantly increase the response induced, whether this was with naive mice or with mice having already been immunized with flu vaccine.
Example 7: Trivalent vaccine composition against the flu comprising low doses of antigens 30 l immunization doses were prepared from the concentrated emulsion of example 1 and a vaccine composition comprising the 3 viral strains of the 2004 campaign (the A/New Caledonia (HIN1) strain, the A/Wyoming (H3N2) strain and the B/Jiangsu strain), these immunization doses having the following compositions:
- 0.1 g of HA of each of the viral strains in PBS buffer, - 0.4 g of HA of each of the viral strains in PBS buffer, - 1.6 g of HA of each of the viral strains in PBS buffer, - 6.3 g of HA of each of the viral strains in PBS buffer, - 0.1 g of HA; 0.75 mg of squalene; 0.11 mg of DehyrnulsTM SMO; 0.143 mg of EumulginTM B1 and 0.138 mg of mannitol in PBS buffer at pH 7.4, - 0.4 g of HA; 0.75 mg of squalene; 0.11 mg of DehymulsTM SMO; 0.143 mg of EumulginTM B1 and 0.138 mg of mannitol in PBS buffer at pH 7.4.
Six groups of eight 8-week-old female BALB/c mice were provided and were administered, on DO, intradermally (internal face of the ear) with a dose of 30 l of one of the compositions indicated below (1 composition per group).
In each group, a 2nd dose having the same nature as the 1 st dose administered was again administered, intradermally, to half the mice on D29.
Blood samples were taken on D22 and on D43 in order to determine the amounts of antibodies induced.
The antibody titers were assayed by ELISA for the antibodies induced at D22 and at D43, with respect to all the strains administered: H1N1, H3N2 and B, and by HAI
with respect to the HIN1 strain only, both at D22 and at D43. The results obtained have been summarized in the table below, in which the titers expressed are the means obtained for each group of mice. As regards the results at D43, the means were determined separately within the same group, for the mice having received 2 doses of vaccine and those having received only one.
Vaccine H1N1 H3N2 B ELISA H1N1 HAI H1N1 HAI titer at composition ELISA titer ELISA titer at D22 titer at D22 D43 at D22 titer at D22 Boosted Non-mice boosted mice 0.1 g HA 3.467 4.131 4.063 57 95 80 0.4 gg HA 3.816 4.527 4.313 73 226 80 1.6 gg HA 4.069 4.831 4.750 147 1280 135 6.3 gg HA 4.534 5.298 4.947 320 1522 320 0.1 g HA
+ emulsion 4.200 5.015 4.807 207 2153 538 0.4 g HA
+ emulsion 4.612 5.482 5.001 453 2560 640 Vaccine H1N1 ELISA titer at H3N2 ELISA titer at B ELISA titer at D43 composition D43 D43 Boosted Non- Boosted Non- Boosted Non-mice boosted mice boosted mice boosted mice mice mice 0.1 g HA 3.833 3.425 4.782 4.174 4.479 3.911 0.4 g HA 4.385 3.599 5.250 4.354 5.053 4.079 1.6 pg HA 4.906 3.876 5.526 4.779 5.458 4.487 6.3 g HA 5.287 4.176 6.073 5.033 5.678 4.773 0.1 g HA 5.210 4.523 5.990 5.264 5.723 4.943 + emulsion 0.4 g HA 5.394 4.790 6.171 5.640 5.962 5.144 + emulsion These results show that, by virtue of the emulsion according to the invention, even with low doses of antigens, very substantial humoral responses were obtained.
Thus, it can be noted that the best results are those obtained with a dose of 0.4 gg of HA of each of the viral strains and an emulsion according to the invention; these results are, very surprisingly, much better than those obtained by using a dose of 6.3 gg of HA
alone. In addition, it is noted that, even in the individuals not given a booster dose, the immune system continues to induce antibodies, whereas this is not the case for the individuals given the non-adjuvanted vaccine antigens.
Example 8: Trivalent vaccine composition against the flu 30 l immunization doses were prepared from the concentrated emulsion of example 1 and a vaccine composition comprising the 3 viral strains of the 2004 campaign (the A/New Caledonia (H1N1) strain, the A/Wyoming (H3N2) strain and the B/Jiangsu strain), these immunization doses having the following compositions:
- 0.1 g of HA of each of the viral strains in PBS buffer, - 0.4 g of HA of each of the viral strains in PBS buffer, - 1.6 g of HA of each of the viral strains in PBS buffer, - 6.3 gg of HA of each of the viral strains in PBS buffer, - 0.1 gg of HA; 0.75 mg of squalene; 0.11 mg of DehymulsTM SMO; 0.143 mg of EumulginTM B1 and 0.138 mg of mannitol in PBS buffer at pH 7.4, - 0.4 g of HA; 0.75 mg of squalene; 0.11 mg of DehymulsTM SMO; 0.143 mg of EumulginTM B1 and 0.138 mg of mannitol in PBS buffer at pH 7.4.
Six groups of eight 8-week-old female C57BL/6J mice were provided and were administered, on DO intradermally (internal face of the ear), with a dose of 30 l of one of the compositions indicated above (1 composition per group).
Blood samples were taken on D23 in order to determine the amounts of antibodies induced.
The antibody titers were assayed by ELISA and by HAI for the antibodies induced with respect to all the strains administered: H1N1, H3N2 and B.
The results obtained have been summarized in the table below, in which the titers expressed are the means obtained for each group of mice.
Composition ELISA ELISA ELISA HAI HAI HAI
0.1 g HA 2.924 3.506 3.920 26 174 95 0.4 g HA 3.673 4.227 4.431 135 269 147 1.6 g HA 3.948 4.593 4.786 160 381 190 6.3 g HA 4.446 5.106 5.190 587 1174 453 0.1 g HA
+ emulsion 4.456 5.192 5.064 349 1974 320 0.4 g HA
+ emulsion 4.659 5.337 5.174 761 2348 494 Again, the results obtained show the great advantage of the emulsion according to the invention, by virtue of which it is possible to very substantially reduce the amounts of antigens present. Specifically, it can be considered, overall, that with only 0.1 g of HA adjuvanted with the emulsion according to the invention, results are obtained that are as good as with an amount of 6.3 g of HA.
Example 9: Trivalent vaccine composition against the flu comprising an emulsion according to the invention or according to the prior art 30 l immunization doses were prepared from the concentrated emulsion of example 1 and a vaccine composition comprising the 3 viral strains of the 2004 campaign (the A/New Caledonia (H1N1) strain, the A/Wyoming (H3N2) strain and the B/Jiangsu strain), these immunization doses having the following compositions:
- 0.3 g of HA of each of the viral strains in PBS buffer, - 6.3 g of HA of each of the viral strains in PBS buffer, - 0.3 g of HA; 0.21 mg of squalene; 0.031 mg of DehymulsTM SMO; 0.040 mg of EumulginTM B1 and 0.039 mg of mannitol in PBS buffer at pH 7.4 (emulsion at 0.7%), - 0.3 g of HA; 0.75 mg of squalene; 0.11 mg of DehymulsTM SMO; 0.143 mg of EumulginTM BI and 0.138 mg of mannitol in PBS buffer at pH 7.4 (emulsion at 2.5%), - 0.3 g of HA; 0.645 mg of squalene; 0.075 mg of TweenTM 80; 0.075 mg of SpanTM 85 (emulsion according to the prior art obtained by microfluidization).
Five groups of eight 8-week-old female BALB/c mice were provided and were administered, on DO intradermally (inteinal face of the ear), with a dose of 30 gl of one of the compositions indicated above (1 composition per group).
To evaluate the amount of antibodies induced, blood samples were taken on D21 and the activity against the A/H1N1 strain, the A/H3N2 strain and the B strain was determined on said blood samples by HAI (hemagglutination inhibition).
The results obtained for each group of mice are represented in the table below.
Composition tested HAI against HAI against HAI against 0.3 g HA 26 174 8 6.3 g HA 247 905 73 0.3 g HA + invention emulsion 95 640 37 at 0.7%
0.3 g HA + invention emulsion 269 1974 73 at 2.5%
0.3 g HA + prior art emulsion 135 987 57 These results show that, with an emulsion obtained according to the invention by virtue of a very simple preparation process consisting of phase inversion by means of a change in temperature, an adjuvant was obtained which is as good as, and even slightly better than, the emulsion of the prior art obtained using very high shear rates.
Example 10: Trivalent vaccine composition against the flu comprising an emulsion according to the invention at various concentrations l immunization doses were prepared from the concentrated emulsion of example 1 and a vaccine composition comprising the 3 viral strains of the 2004 campaign (the A/New Caledonia (H1N1) strain, the A/Wyoming (H3N2) strain and the B/Jiangsu strain), these immunization doses having the following compositions:
- 0.3 g of HA of each of the viral strains in PBS buffer, - 6.3 gg of HA of each of the viral strains in PBS buffer, - 0.3 g of HA of each of the viral strains; 0.12 mg of squalene; 0.018 mg of DehymulsTM SMO; 0.023 mg of EumulginTM B1 and 0.022 mg of mannitol in PBS buffer at pH 7.4 (emulsion at 0.4%), - 0.3 g of HA of each of the viral strains; 0.299 mg of squalene; 0.044 mg of DehymulsTM SMO; 0.057 mg of EumulginTM BI and 0.055 mg of mannitol in PBS buffer at pH 7.4 (emulsion at 1%), - 0.3 g of HA of each of the viral strains; 0.75 mg of squalene; 0.11 mg of DehymulsTM SMO; 0.143 mg of EumulginTM B1 and 0.138 mg of mannitol in PBS buffer at pH 7.4 (emulsion at 2.5%).
Five groups of eight 8-week-old female BALB/c mice were provided and were administered, on DO intradermally (internal face of the ear), with a dose of 30 l of one of the compositions indicated above (I composition per group).
In order to evaluate the amount of antibodies induced, blood samples were taken at D21 and the anti-H1N1 antibodies, the anti-H3N2 antibodies and the anti-B
antibodies were determined on these blood samples by ELISA, and the activity against the A/H1N1 strain, the A/H3N2 strain and the B strain was determined by HAI (hemagglutination inhibition).
The results obtained are represented in the table below in the form of means for each of the groups; the ELISA results are expressed in log, o of arbitrary ELISA
units and the HAI results are the mean arithmetic titers of the inverses of dilutions.
0.1 g HA 2.924 3.506 3.920 26 174 95 0.4 g HA 3.673 4.227 4.431 135 269 147 1.6 g HA 3.948 4.593 4.786 160 381 190 6.3 g HA 4.446 5.106 5.190 587 1174 453 0.1 g HA
+ emulsion 4.456 5.192 5.064 349 1974 320 0.4 g HA
+ emulsion 4.659 5.337 5.174 761 2348 494 Again, the results obtained show the great advantage of the emulsion according to the invention, by virtue of which it is possible to very substantially reduce the amounts of antigens present. Specifically, it can be considered, overall, that with only 0.1 g of HA adjuvanted with the emulsion according to the invention, results are obtained that are as good as with an amount of 6.3 g of HA.
Example 9: Trivalent vaccine composition against the flu comprising an emulsion according to the invention or according to the prior art 30 l immunization doses were prepared from the concentrated emulsion of example 1 and a vaccine composition comprising the 3 viral strains of the 2004 campaign (the A/New Caledonia (H1N1) strain, the A/Wyoming (H3N2) strain and the B/Jiangsu strain), these immunization doses having the following compositions:
- 0.3 g of HA of each of the viral strains in PBS buffer, - 6.3 g of HA of each of the viral strains in PBS buffer, - 0.3 g of HA; 0.21 mg of squalene; 0.031 mg of DehymulsTM SMO; 0.040 mg of EumulginTM B1 and 0.039 mg of mannitol in PBS buffer at pH 7.4 (emulsion at 0.7%), - 0.3 g of HA; 0.75 mg of squalene; 0.11 mg of DehymulsTM SMO; 0.143 mg of EumulginTM BI and 0.138 mg of mannitol in PBS buffer at pH 7.4 (emulsion at 2.5%), - 0.3 g of HA; 0.645 mg of squalene; 0.075 mg of TweenTM 80; 0.075 mg of SpanTM 85 (emulsion according to the prior art obtained by microfluidization).
Five groups of eight 8-week-old female BALB/c mice were provided and were administered, on DO intradermally (inteinal face of the ear), with a dose of 30 gl of one of the compositions indicated above (1 composition per group).
To evaluate the amount of antibodies induced, blood samples were taken on D21 and the activity against the A/H1N1 strain, the A/H3N2 strain and the B strain was determined on said blood samples by HAI (hemagglutination inhibition).
The results obtained for each group of mice are represented in the table below.
Composition tested HAI against HAI against HAI against 0.3 g HA 26 174 8 6.3 g HA 247 905 73 0.3 g HA + invention emulsion 95 640 37 at 0.7%
0.3 g HA + invention emulsion 269 1974 73 at 2.5%
0.3 g HA + prior art emulsion 135 987 57 These results show that, with an emulsion obtained according to the invention by virtue of a very simple preparation process consisting of phase inversion by means of a change in temperature, an adjuvant was obtained which is as good as, and even slightly better than, the emulsion of the prior art obtained using very high shear rates.
Example 10: Trivalent vaccine composition against the flu comprising an emulsion according to the invention at various concentrations l immunization doses were prepared from the concentrated emulsion of example 1 and a vaccine composition comprising the 3 viral strains of the 2004 campaign (the A/New Caledonia (H1N1) strain, the A/Wyoming (H3N2) strain and the B/Jiangsu strain), these immunization doses having the following compositions:
- 0.3 g of HA of each of the viral strains in PBS buffer, - 6.3 gg of HA of each of the viral strains in PBS buffer, - 0.3 g of HA of each of the viral strains; 0.12 mg of squalene; 0.018 mg of DehymulsTM SMO; 0.023 mg of EumulginTM B1 and 0.022 mg of mannitol in PBS buffer at pH 7.4 (emulsion at 0.4%), - 0.3 g of HA of each of the viral strains; 0.299 mg of squalene; 0.044 mg of DehymulsTM SMO; 0.057 mg of EumulginTM BI and 0.055 mg of mannitol in PBS buffer at pH 7.4 (emulsion at 1%), - 0.3 g of HA of each of the viral strains; 0.75 mg of squalene; 0.11 mg of DehymulsTM SMO; 0.143 mg of EumulginTM B1 and 0.138 mg of mannitol in PBS buffer at pH 7.4 (emulsion at 2.5%).
Five groups of eight 8-week-old female BALB/c mice were provided and were administered, on DO intradermally (internal face of the ear), with a dose of 30 l of one of the compositions indicated above (I composition per group).
In order to evaluate the amount of antibodies induced, blood samples were taken at D21 and the anti-H1N1 antibodies, the anti-H3N2 antibodies and the anti-B
antibodies were determined on these blood samples by ELISA, and the activity against the A/H1N1 strain, the A/H3N2 strain and the B strain was determined by HAI (hemagglutination inhibition).
The results obtained are represented in the table below in the form of means for each of the groups; the ELISA results are expressed in log, o of arbitrary ELISA
units and the HAI results are the mean arithmetic titers of the inverses of dilutions.
Anti-H 1 N 1 Anti-H3N2 Anti-B
Composition tested ELISA HAI ELISA HAI ELISA HAI
0.3 g HA 3.864 67 4.594 320 4.406 31 6.3 g HA 4.478 269 5.041 1660 5.053 135 0.3 g HA + invention 4.053 108 4.827 525 4.545 54 emulsion at 0.4%
0.3 g HA + invention 4.312 269 5.074 1174 4.733 123 emulsion at 1%
0.3 g HA + 4.425 293 5.200 1974 4.840 123 invention emulsion at 2.5%
These results confirm once again that, whatever the strain evaluated, the emulsion according to the invention made it possible, with a very low dose of antigens, to obtain a very substantial immune system response.
Example 11: Preparation of a lyophilizable composition The process was carried out as in example 1, but using water instead of the buffer; the emulsion obtained was subsequently diluted with an aqueous solution comprising mannitol, sucrose and dodecylmaltoside, in order to obtain an emulsion whose final composition was as follows:
- 5% of squalene, - 0.95% of polyoxyethylene cetostearyl ether, - 0.75% of sorbitan monooleate - 3% of mannitol, - 2% of dodecylmaltoside, - 6% of sucrose.
This emulsion was lyophilized and conserved at 4 C for 3 months; then, after reconstitution, it was noted that its properties were conserved, in particular its monodisperse emulsion qualities, with d50 and d90 values close to those measured before lyophilization.
This emulsion was able to be diluted 50/50 with a solution comprising vaccine antigens in order to obtain a vaccine composition.
Composition tested ELISA HAI ELISA HAI ELISA HAI
0.3 g HA 3.864 67 4.594 320 4.406 31 6.3 g HA 4.478 269 5.041 1660 5.053 135 0.3 g HA + invention 4.053 108 4.827 525 4.545 54 emulsion at 0.4%
0.3 g HA + invention 4.312 269 5.074 1174 4.733 123 emulsion at 1%
0.3 g HA + 4.425 293 5.200 1974 4.840 123 invention emulsion at 2.5%
These results confirm once again that, whatever the strain evaluated, the emulsion according to the invention made it possible, with a very low dose of antigens, to obtain a very substantial immune system response.
Example 11: Preparation of a lyophilizable composition The process was carried out as in example 1, but using water instead of the buffer; the emulsion obtained was subsequently diluted with an aqueous solution comprising mannitol, sucrose and dodecylmaltoside, in order to obtain an emulsion whose final composition was as follows:
- 5% of squalene, - 0.95% of polyoxyethylene cetostearyl ether, - 0.75% of sorbitan monooleate - 3% of mannitol, - 2% of dodecylmaltoside, - 6% of sucrose.
This emulsion was lyophilized and conserved at 4 C for 3 months; then, after reconstitution, it was noted that its properties were conserved, in particular its monodisperse emulsion qualities, with d50 and d90 values close to those measured before lyophilization.
This emulsion was able to be diluted 50/50 with a solution comprising vaccine antigens in order to obtain a vaccine composition.
Example 12: Comparison of the adjuvant effect of the emulsion according to the invention and of a surfactant present in the emulsion The intention was to evaluate the adjuvant activity of the emulsion according to the invention, compared with that of the surfactant EumulginTM B1 which is present in the emulsion.
For this, a test was carried out on mice using flu antigens.
To this end, flu virus antigens were available, obtained according to the process described in the examples of application WO 96/05294, with the exception of the fact that the viral strain used was the A/New Caledonia H1N1 strain. A vaccine composition comprising the 3 viral strains of the 2004 campaign (the A/New Caledonia (H1N1) strain, the A/Wyoming (H3N2) strain and the B/Jiangsu strain) was also available.
100 l immunization doses were prepared from the concentrated emulsion obtained according to the invention and described in example 1, from EumulginTM B 1, and from the flu virus antigen compositions, these immunization doses having the following compositions:
- 1 g of HA of the H1N1 strain in PBS buffer at pH 7.4;
- 5 g of HA of the H1N1 strain in PBS buffer at pH 7.4;
- 1 g of HA of the H1N1 strain; 2.5 mg of squalene; 0.37 mg of DehymulsTM
SMO; 0.48 mg of EumulginTM B 1 and 0.46 mg of mannitol in PBS buffer at pH7.4;
- 1 g of HA of the H1N1 strain and 0.48 mg of EumulginTM B1 in PBS buffer at pH 7.4 ;
- 0.33 g of HA of each of the viral stains in PBS buffer at pH 7.4;
- 1.66 g of HA of each of the viral stains in PBS buffer at pH 7.4;
- 0.33 g of HA of each of the viral stains; 2.5mg of squalene; 0.37 mg of DehymulsTM SMO; 0.48 mg of EumulginTM B 1 and 0.46 mg of mannitol in PBS buffer at pH 7.4;
- 0.33 gg of HA of each of the viral stains and 0.48 mg of EumulginTM B 1 in PBS buffer at pH 7.4.
For this, a test was carried out on mice using flu antigens.
To this end, flu virus antigens were available, obtained according to the process described in the examples of application WO 96/05294, with the exception of the fact that the viral strain used was the A/New Caledonia H1N1 strain. A vaccine composition comprising the 3 viral strains of the 2004 campaign (the A/New Caledonia (H1N1) strain, the A/Wyoming (H3N2) strain and the B/Jiangsu strain) was also available.
100 l immunization doses were prepared from the concentrated emulsion obtained according to the invention and described in example 1, from EumulginTM B 1, and from the flu virus antigen compositions, these immunization doses having the following compositions:
- 1 g of HA of the H1N1 strain in PBS buffer at pH 7.4;
- 5 g of HA of the H1N1 strain in PBS buffer at pH 7.4;
- 1 g of HA of the H1N1 strain; 2.5 mg of squalene; 0.37 mg of DehymulsTM
SMO; 0.48 mg of EumulginTM B 1 and 0.46 mg of mannitol in PBS buffer at pH7.4;
- 1 g of HA of the H1N1 strain and 0.48 mg of EumulginTM B1 in PBS buffer at pH 7.4 ;
- 0.33 g of HA of each of the viral stains in PBS buffer at pH 7.4;
- 1.66 g of HA of each of the viral stains in PBS buffer at pH 7.4;
- 0.33 g of HA of each of the viral stains; 2.5mg of squalene; 0.37 mg of DehymulsTM SMO; 0.48 mg of EumulginTM B 1 and 0.46 mg of mannitol in PBS buffer at pH 7.4;
- 0.33 gg of HA of each of the viral stains and 0.48 mg of EumulginTM B 1 in PBS buffer at pH 7.4.
Eight groups of 8 female BALB/c mice were provided and were immunized by means of a single intramuscular injection on DO. Blood samples were taken on D21 and in order to evaluate by ELISA assay their content of total antibodies induced against the A/H1N1 flu strain or against each of the strains of the trivalent vaccine.
The antibody titers, indicated in the table below, are expressed as the log10 value of arbitrary ELISA units, with a detection threshold of 1.3 logl0.
Titers at D21 Titers at D35 Immunization dose compositions H1N1 H3N2 B H1N1 H3N2 B
H1N1 at 1 gg 2.745 2.848 H1N1 at 5 g 3.057 3.139 H1N1 at 1 gg+ invention emulsion 4.002 4.128 HIN1 at 1 g + EumulginTMB1 3.019 3.119 Trivalent vaccine at 1 g of total HA 3.111 3.718 3.706 3.218 4.147 3.935 Trivalent vaccine at 5 g of total HA 3.692 4.386 3.975 3.776 4.632 4.225 Trivalent vaccine at 1 g of total HA 4.252 5.002 4.596 4.186 5.214 4.897 + invention emulsion Trivalent vaccine at 1 gg of total HA 3.146 3.712 3.950 3.241 4.177 4.242 + EumulginTM B 1 The results obtained in this test confirm those already obtained in previous tests, namely that the emulsion according to the invention makes it possible to greatly reduce the dose of antigens for the same immune system response; a better response was in fact obtained using the emulsion according to the invention and only I
g of HA rather than using a dose of 5 gg of HA without adjuvant.
It is also observed that the surfactant used does not really exhibit any adjuvant effect when it is used alone, whereas the emulsion according to the invention itself produces a highly adjuvant effect with respect to all the strains tested.
The antibody titers, indicated in the table below, are expressed as the log10 value of arbitrary ELISA units, with a detection threshold of 1.3 logl0.
Titers at D21 Titers at D35 Immunization dose compositions H1N1 H3N2 B H1N1 H3N2 B
H1N1 at 1 gg 2.745 2.848 H1N1 at 5 g 3.057 3.139 H1N1 at 1 gg+ invention emulsion 4.002 4.128 HIN1 at 1 g + EumulginTMB1 3.019 3.119 Trivalent vaccine at 1 g of total HA 3.111 3.718 3.706 3.218 4.147 3.935 Trivalent vaccine at 5 g of total HA 3.692 4.386 3.975 3.776 4.632 4.225 Trivalent vaccine at 1 g of total HA 4.252 5.002 4.596 4.186 5.214 4.897 + invention emulsion Trivalent vaccine at 1 gg of total HA 3.146 3.712 3.950 3.241 4.177 4.242 + EumulginTM B 1 The results obtained in this test confirm those already obtained in previous tests, namely that the emulsion according to the invention makes it possible to greatly reduce the dose of antigens for the same immune system response; a better response was in fact obtained using the emulsion according to the invention and only I
g of HA rather than using a dose of 5 gg of HA without adjuvant.
It is also observed that the surfactant used does not really exhibit any adjuvant effect when it is used alone, whereas the emulsion according to the invention itself produces a highly adjuvant effect with respect to all the strains tested.
Claims (31)
1. An oil-in-water adjuvant emulsion characterized in that it comprises at least:
- squalene, - an aqueous solvent, - a nonionic surfactant which is a polyoxyethylene alkyl ether, - a hydrophobic nonionic surfactant, in that it is thermoreversible and in that 90% of the population by volume of the oil drops has a size less than 200 nm.
- squalene, - an aqueous solvent, - a nonionic surfactant which is a polyoxyethylene alkyl ether, - a hydrophobic nonionic surfactant, in that it is thermoreversible and in that 90% of the population by volume of the oil drops has a size less than 200 nm.
2. The emulsion as claimed in the preceding claim, characterized in that 90%
of the population by volume of the oil drops has a size less than 160 nm.
of the population by volume of the oil drops has a size less than 160 nm.
3. The emulsion as claimed in one of the preceding claims, characterized in that 90%
of the population by volume of the oil drops has a size less than 150 nm.
of the population by volume of the oil drops has a size less than 150 nm.
4. The emulsion as claimed in one of the preceding claims, characterized in that 50%
of the population by volume of the oil drops has a size less than 100 nm.
of the population by volume of the oil drops has a size less than 100 nm.
5. The emulsion as claimed in one of the preceding claims, characterized in that 50%
of the population by volume of the oil drops has a size less than 90 nm.
of the population by volume of the oil drops has a size less than 90 nm.
6. The emulsion as claimed in one of the preceding claims, characterized in that it also comprises at least one alditol.
7. The emulsion as claimed in claim 1, characterized in that the hydrophobic nonionic surfactant comprises a sorbitan ester or a mannide ester.
8. The emulsion as claimed in one of the preceding claims, characterized in that the polyoxyethylene alkyl ether is polyoxyethylene(12) cetostearyl ether.
9. The emulsion as claimed in one of the preceding claims, characterized in that the alditol is chosen from glycerol, erythritol, xylitol, sorbitol and mannitol.
10. The emulsion as claimed in one of the preceding claims, characterized in that the hydrophobic nonionic surfactant is sorbitan monooleate.
11. The emulsion as claimed in one of the preceding claims, characterized in that the amount of squalene is between 5 and 45%.
12. The emulsion as claimed in one of the preceding claims, characterized in that the amount of polyoxyethylene alkyl ether-based surfactant is between 0.9 and 9%.
13. The emulsion as claimed in one of the preceding claims, characterized in that the amount of hydrophobic nonionic surfactant is between 0.7 and 7%.
14. The adjuvant emulsion as claimed in one of the preceding claims, characterized in that it comprises:
.cndot. 32.5% of squalene, .cndot. 6.18 % of polyoxyethylene(12) cetostearyl ether, .cndot. 4.82% of sorbitan monooleate, .cndot. 6% of mannitol.
.cndot. 32.5% of squalene, .cndot. 6.18 % of polyoxyethylene(12) cetostearyl ether, .cndot. 4.82% of sorbitan monooleate, .cndot. 6% of mannitol.
15. The emulsion as claimed in one of the preceding claims, characterized in that it also comprises an alkylpolyglycoside.
16. The emulsion as claimed in one of the preceding claims, characterized in that it also comprises a cryoprotective agent.
17. The use of an emulsion as claimed in one of the preceding claims, for preparing an immunogenic composition intended to be administered intramuscularly.
18. The use of an emulsion as claimed in one of claims 1 to 16, for preparing an immunogenic composition intended to be administered intradermally.
19. The use of an emulsion as claimed in one of claims 1 to 16, for preparing an immunogenic composition intended to be administered subcutaneously.
20. The use of an emulsion as claimed in one of claims 1 to 16, for preparing an immunogenic composition intended to be administered against the flu.
21. The use of an emulsion as claimed in one of claims 1 to 16, for preparing an immunogenic composition intended to be administered against AIDS.
22. The use of an emulsion as claimed in one of claims 1 to 16, for preparing an immunogenic composition intended to be administered against human cytomegalovirus pathologies.
23. A process for preparing an immunogenic composition, according to which at least one vaccine antigen is mixed with an oil-in-water emulsion, characterized in that the oil-in-water emulsion is obtained by means of a phase inversion temperature process.
24. The process as claimed in the preceding claim, characterized in that it comprises at least a step for preparing the oil-in-water emulsion by cooling a water-in-oil inverse emulsion, which comprises at least:
- squalene, - an aqueous solvent, - a hydrophilic nonionic surfactant which is a polyoxyethylene alkyl ether, - a hydrophobic nonionic surfactant.
- squalene, - an aqueous solvent, - a hydrophilic nonionic surfactant which is a polyoxyethylene alkyl ether, - a hydrophobic nonionic surfactant.
25. The process as claimed in the preceding claim, characterized in that the water-in-oil inverse emulsion is obtained by mixing squalene, an aqueous solvent, a nonionic surfactant which is a polyoxyethylene alkyl ether, and a hydrophobic nonionic surfactant so as to obtain, first of all, an oil-in-water coarse emulsion, and this emulsion is then heated to at least the phase-inversion temperature so as to obtain the inverse emulsion.
26. The process as claimed in claim 24, according to which:
- on the one hand, an aqueous phase comprising an aqueous solvent and a surfactant which is a polyoxyethylene alkyl ether and, on the other hand, an oily phase comprising squalene and a hydrophobic surfactant are heated, separately, to a temperature at least equal to the phase-inversion temperature, and then - the 2 phases are mixed so as to obtain a water-in-oil inverse emulsion.
- on the one hand, an aqueous phase comprising an aqueous solvent and a surfactant which is a polyoxyethylene alkyl ether and, on the other hand, an oily phase comprising squalene and a hydrophobic surfactant are heated, separately, to a temperature at least equal to the phase-inversion temperature, and then - the 2 phases are mixed so as to obtain a water-in-oil inverse emulsion.
27. The process as claimed in claim 24, according to which:
- on the one hand, an aqueous phase comprising an aqueous solvent and a surfactant which is a polyoxyethylene alkyl ether and, on the second hand, an oily phase comprising squalene and a hydrophobic surfactant are heated, separately, to a temperature below the phase-inversion temperature of the emulsion, - the 2 phases are then mixed so as to obtain an oil-in-water emulsion, - the oil-in-water emulsion obtained is then heated to a temperature at least equal to the phase-inversion temperature so as to obtain a water-in-oil inverse emulsion.
- on the one hand, an aqueous phase comprising an aqueous solvent and a surfactant which is a polyoxyethylene alkyl ether and, on the second hand, an oily phase comprising squalene and a hydrophobic surfactant are heated, separately, to a temperature below the phase-inversion temperature of the emulsion, - the 2 phases are then mixed so as to obtain an oil-in-water emulsion, - the oil-in-water emulsion obtained is then heated to a temperature at least equal to the phase-inversion temperature so as to obtain a water-in-oil inverse emulsion.
28. The process as claimed in one of claims 23 to 27, characterized in that the phase-inversion temperature is between 45 and 80°C.
29. The process as claimed in the preceding claim, characterized in that the phase-inversion temperature is between 50 and 65°C.
30. The process as claimed in one of claims 23 to 29, characterized in that it also comprises at least one lyophilization step.
31. An immunogenic composition, characterized in that it can be obtained by means of the process as claimed in one of claims 23 to 30.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0507240 | 2005-07-07 | ||
| FR0507240A FR2888117B1 (en) | 2005-07-07 | 2005-07-07 | VACCINE COMPOSITION COMPRISING A THERMOREVERSIBLE EMULSION |
| FR0508310 | 2005-08-04 | ||
| FR0508310 | 2005-08-04 | ||
| PCT/FR2006/001635 WO2007006939A2 (en) | 2005-07-07 | 2006-07-07 | Thermoreversible immuno-adjuvant emulsion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2613732A1 true CA2613732A1 (en) | 2007-01-18 |
| CA2613732C CA2613732C (en) | 2013-12-10 |
Family
ID=37637538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2613732A Active CA2613732C (en) | 2005-07-07 | 2006-07-07 | Thermoreversible immuno-adjuvant emulsion |
Country Status (24)
| Country | Link |
|---|---|
| EP (2) | EP2080522B1 (en) |
| JP (1) | JP5300475B2 (en) |
| KR (1) | KR101328638B1 (en) |
| CN (1) | CN101217977B (en) |
| AR (1) | AR054822A1 (en) |
| AT (1) | ATE424845T1 (en) |
| AU (1) | AU2006268466B2 (en) |
| BR (1) | BRPI0614053A2 (en) |
| CA (1) | CA2613732C (en) |
| CY (2) | CY1108994T1 (en) |
| DE (1) | DE602006005671D1 (en) |
| DK (2) | DK1904099T3 (en) |
| EA (1) | EA012376B1 (en) |
| ES (2) | ES2390104T3 (en) |
| IL (1) | IL187967A0 (en) |
| MX (1) | MX2007016412A (en) |
| NO (1) | NO336369B1 (en) |
| NZ (1) | NZ564173A (en) |
| PL (2) | PL2080522T3 (en) |
| PT (2) | PT2080522E (en) |
| SG (1) | SG163584A1 (en) |
| SI (2) | SI1904099T1 (en) |
| TN (1) | TNSN08001A1 (en) |
| WO (1) | WO2007006939A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8933033B2 (en) | 2009-10-09 | 2015-01-13 | Cbio Limited | Chaperonin 10 variants |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006100111A1 (en) | 2005-03-23 | 2006-09-28 | Glaxosmithkline Biologicals S.A. | Composition |
| AR054822A1 (en) * | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | ADMISSION IMMUNE EMULSION |
| US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| PT2368572T (en) | 2005-11-04 | 2020-06-16 | Seqirus Uk Ltd | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| US20090304742A1 (en) * | 2005-11-04 | 2009-12-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines with reduced amount of emulsion adjuvant |
| AU2011213757B2 (en) * | 2005-11-04 | 2013-07-25 | Seqirus UK Limited | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
| EP2043682B1 (en) | 2006-07-17 | 2014-04-02 | GlaxoSmithKline Biologicals S.A. | Influenza vaccine |
| GB0622282D0 (en) | 2006-11-08 | 2006-12-20 | Novartis Ag | Quality control methods |
| US9452209B2 (en) | 2007-04-20 | 2016-09-27 | Glaxosmithkline Biologicals Sa | Influenza vaccine |
| US9562075B2 (en) * | 2007-05-31 | 2017-02-07 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Intradermal HPV peptide vaccination |
| CN101428145B (en) * | 2007-11-05 | 2013-01-02 | 北京生泰尔生物科技有限公司 | Novel vaccine adjuvant |
| US8506966B2 (en) | 2008-02-22 | 2013-08-13 | Novartis Ag | Adjuvanted influenza vaccines for pediatric use |
| WO2009109550A1 (en) | 2008-03-05 | 2009-09-11 | Sanofi Pasteur | Process for stabilizing an adjuvant containing vaccine composition |
| KR101707569B1 (en) | 2008-08-01 | 2017-02-16 | 감마 백신즈 피티와이 리미티드 | Influenza vaccines |
| CN102307590A (en) | 2009-02-10 | 2012-01-04 | 诺华有限公司 | Influenza vaccines with reduced amounts of squalene |
| US10568859B2 (en) | 2009-02-25 | 2020-02-25 | Mayne Pharma Llc | Topical foam composition |
| GB0919117D0 (en) | 2009-10-30 | 2009-12-16 | Glaxosmithkline Biolog Sa | Process |
| GB201009673D0 (en) * | 2010-06-10 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel process |
| BR112013013702A2 (en) | 2010-12-03 | 2016-09-13 | Sanofi Pasteur Ltd | composition for immunization against streptococcus pneumoniae |
| AU2012211043B2 (en) | 2011-01-27 | 2017-04-06 | Gamma Vaccines Pty Limited | Combination vaccines |
| EP2578974A1 (en) | 2011-10-05 | 2013-04-10 | Sanofi Pasteur Sa | Process line for the production of freeze-dried particles |
| ES2732229T3 (en) | 2012-03-23 | 2019-11-21 | Pitney Pharmaceuticals Pty Ltd | Kinase inhibitors for cancer treatment |
| IN2014DN10408A (en) | 2012-06-05 | 2015-08-14 | Univ Australian | |
| WO2013184900A2 (en) | 2012-06-06 | 2013-12-12 | Sanofi Pasteur Biologics, Llc | Immunogenic compositions and related methods |
| JP2015524422A (en) | 2012-07-24 | 2015-08-24 | サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ | Vaccine composition |
| EP2877208B1 (en) | 2012-07-24 | 2021-05-12 | Sanofi Pasteur | Vaccine compositions for the prevention of dengue virus infection |
| NZ729555A (en) | 2012-08-06 | 2017-08-25 | Pitney Pharmaceuticals Pty Ltd | Compounds for the treatment of mtor pathway related diseases |
| CN103784953B (en) * | 2012-10-26 | 2018-04-10 | 上海医药工业研究院 | Oil-in-water type Submicron Emulsion as vaccine adjuvant and preparation method thereof |
| WO2014083194A1 (en) | 2012-11-30 | 2014-06-05 | Sanofi Pasteur | Methods for inducing antibodies |
| US11369666B2 (en) | 2012-12-17 | 2022-06-28 | Newsouth Innovations Pty Limited | Treatment of diseases involving mucin |
| EP3446708A1 (en) | 2012-12-24 | 2019-02-27 | Cell Ideas Pty Ltd. | Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy |
| EP3016968B1 (en) | 2013-07-01 | 2019-06-26 | Newsouth Innovations Pty Limited | Diagnosis and treatment of autoimmune diseases |
| CN105267963A (en) * | 2014-06-18 | 2016-01-27 | 潘皓 | Preparation method for nanoemulsion vaccine auxiliary agent |
| AU2015293983B2 (en) | 2014-07-21 | 2017-02-09 | Sanofi Pasteur Sa | Liquid feeding device for the generation of droplets |
| CN116603058A (en) | 2015-03-26 | 2023-08-18 | Gpn疫苗有限公司 | Streptococcus vaccine |
| CN105251002B (en) * | 2015-11-13 | 2019-02-15 | 中国人民解放军第三军医大学 | A kind of oil-in-water type nano-emulsion adjuvant and its MRSA nano emulsion adjuvant vaccine and preparation method |
| WO2017137085A1 (en) | 2016-02-11 | 2017-08-17 | Sanofi Pasteur | Meningitidis vaccines comprising subtilinases |
| RU2018137034A (en) * | 2016-03-23 | 2020-04-23 | Интервет Интернэшнл Б.В. | PCV2 COMBINED VACCINE AND MYCOPLASMA HYOPNEUMONIAE INFECTION |
| ES2968923T3 (en) * | 2016-08-10 | 2024-05-14 | Celltrion Inc | Stable liquid pharmaceutical preparation of influenza virus antibody |
| AU2018241252A1 (en) | 2017-03-30 | 2019-10-03 | The University Of Queensland | Chimeric molecules and uses thereof |
| WO2021231729A1 (en) | 2020-05-13 | 2021-11-18 | Sanofi | Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza |
| WO2022046634A1 (en) | 2020-08-24 | 2022-03-03 | Sanofi Pasteur Inc. | Vaccines against sars-cov-2 infections |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6100064A (en) | 1984-04-06 | 2000-08-08 | Chiron Corporation | Secreted viral proteins useful for vaccines and diagnostics |
| ATE246244T1 (en) | 1988-01-29 | 2003-08-15 | Aventis Pasteur | RECOMBINANT CMV NEUTRALIZATION PROTEINS |
| JPH0832638B2 (en) * | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | Adjuvant formulation comprising submicron oil droplet emulsion |
| FR2723740B1 (en) | 1994-08-16 | 1996-11-08 | Pasteur Merieux Serums Vacc | PROCESS FOR THE PREPARATION OF INFLUENZA VIRUS ANTIGENS, ANTIGENS OBTAINED AND THEIR APPLICATIONS |
| US6787523B1 (en) * | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| FR2773156B1 (en) | 1997-12-26 | 2000-03-31 | Biovacs Inc | NOVEL ANTI-RETROVIRAL IMMUNOGENS (TOXOIDS), NOVEL PREPARATION METHODS AND APPLICATION TO AIDS PREVENTION AND TREATMENT |
| US6299848B1 (en) * | 1998-09-25 | 2001-10-09 | Hamon Research-Cottrell | Process for removing sulfur dioxide out of a gas |
| AU764969B2 (en) * | 1999-04-19 | 2003-09-04 | Smithkline Beecham Biologicals (Sa) | Vaccines |
| US20030129251A1 (en) * | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
| ATE444735T1 (en) * | 2001-03-21 | 2009-10-15 | Madash Llc | THERMALLY REVERSIBLE WATER-IN-OIL-IN-WATER EMULSIONS |
| AR054822A1 (en) * | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | ADMISSION IMMUNE EMULSION |
-
2006
- 2006-07-06 AR ARP060102917A patent/AR054822A1/en unknown
- 2006-07-07 ES ES09152313T patent/ES2390104T3/en active Active
- 2006-07-07 PL PL09152313T patent/PL2080522T3/en unknown
- 2006-07-07 PT PT09152313T patent/PT2080522E/en unknown
- 2006-07-07 MX MX2007016412A patent/MX2007016412A/en active IP Right Grant
- 2006-07-07 DE DE602006005671T patent/DE602006005671D1/en active Active
- 2006-07-07 SG SG201004919-5A patent/SG163584A1/en unknown
- 2006-07-07 DK DK06778810T patent/DK1904099T3/en active
- 2006-07-07 SI SI200630298T patent/SI1904099T1/en unknown
- 2006-07-07 BR BRPI0614053-0A patent/BRPI0614053A2/en not_active IP Right Cessation
- 2006-07-07 EA EA200800271A patent/EA012376B1/en not_active IP Right Cessation
- 2006-07-07 SI SI200631423T patent/SI2080522T1/en unknown
- 2006-07-07 KR KR1020087002704A patent/KR101328638B1/en active IP Right Grant
- 2006-07-07 EP EP09152313A patent/EP2080522B1/en active Active
- 2006-07-07 EP EP06778810A patent/EP1904099B1/en active Active
- 2006-07-07 CA CA2613732A patent/CA2613732C/en active Active
- 2006-07-07 NZ NZ564173A patent/NZ564173A/en not_active IP Right Cessation
- 2006-07-07 ES ES06778810T patent/ES2322102T3/en active Active
- 2006-07-07 AT AT06778810T patent/ATE424845T1/en active
- 2006-07-07 DK DK09152313.4T patent/DK2080522T3/en active
- 2006-07-07 AU AU2006268466A patent/AU2006268466B2/en active Active
- 2006-07-07 PT PT06778810T patent/PT1904099E/en unknown
- 2006-07-07 WO PCT/FR2006/001635 patent/WO2007006939A2/en active Application Filing
- 2006-07-07 JP JP2008519966A patent/JP5300475B2/en active Active
- 2006-07-07 PL PL06778810T patent/PL1904099T3/en unknown
- 2006-07-07 CN CN2006800248369A patent/CN101217977B/en active Active
-
2007
- 2007-12-06 IL IL187967A patent/IL187967A0/en not_active IP Right Cessation
-
2008
- 2008-01-04 TN TNP2008000001A patent/TNSN08001A1/en unknown
- 2008-01-31 NO NO20080585A patent/NO336369B1/en not_active IP Right Cessation
-
2009
- 2009-04-27 CY CY20091100455T patent/CY1108994T1/en unknown
-
2012
- 2012-10-03 CY CY20121100915T patent/CY1113414T1/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8933033B2 (en) | 2009-10-09 | 2015-01-13 | Cbio Limited | Chaperonin 10 variants |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2613732C (en) | Thermoreversible immuno-adjuvant emulsion | |
| US8703095B2 (en) | Immuno-adjuvant emulsion | |
| US9504659B2 (en) | Thermoreversible oil-in-water emulsion | |
| AU2009248810A1 (en) | Nanoemulsion vaccines | |
| CA3127639A1 (en) | Oil/surfactant mixtures for self-emulsification | |
| JP2014520805A (en) | Human respiratory syncytial virus vaccine | |
| Lin et al. | Oil-in-ionic liquid nanoemulsion-based adjuvant simultaneously enhances the stability and immune responses of inactivated foot-and-mouth disease virus | |
| Macedo et al. | Evaluation of different adjuvants formulations for bluetongue vaccine | |
| Zhang et al. | Development and efficacy evaluation of a novel water-in-oil-in-water adjuvant for an inactivated foot-and-mouth disease vaccine | |
| US20240165224A1 (en) | Immunogenic compositions | |
| Lodaya | Self-Emulsifying Adjuvant Systems Containing Alpha-Tocopherol for Subunit Vaccines | |
| FR2888117A1 (en) | Oil-in-water adjuvant emulsion, useful in immunogenic composition, comprises squalene, aqueous solvent, polyoxyethylene alkyl ether hydrophilic nonionic surfactant, and hydrophobic nonionic surfactant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |